



Published in final edited form as:

*Epidemiology*. 2020 January ; 31(1): 43–64. doi:10.1097/EDE.0000000000001116.

## The use of test-negative controls to monitor vaccine effectiveness: a systematic review of methodology

Huiying Chua<sup>1</sup>, Shuo Feng<sup>1</sup>, Joseph A. Lewnard<sup>2</sup>, Sheena G. Sullivan<sup>3,4,5</sup>, Christopher C. Blyth<sup>6,7,8</sup>, Marc Lipsitch<sup>9,10</sup>, Benjamin J. Cowling<sup>1</sup>

<sup>1</sup>World Health Organization Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, The University of Hong Kong, Hong Kong Special Administrative Region, China.

<sup>2</sup>Division of Epidemiology, School of Public Health, University of California, Berkeley, Berkeley, California, USA.

<sup>3</sup>WHO Collaborating Center for Reference and Research on Influenza at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.

<sup>4</sup>Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, California, USA.

<sup>5</sup>Centre for Epidemiology and Biostatistics, School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia.

<sup>6</sup>Division of Paediatrics, School of Medicine, Faculty of Health and Medical Sciences, The University of Western Australia, Perth, Western Australia, Australia.

<sup>7</sup>Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Perth, Western Australia, Australia.

<sup>8</sup>Department of Infectious Diseases, Perth Children's Hospital, Perth, Western Australia, Australia.

<sup>9</sup>Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.

<sup>10</sup>Center for Communicable Disease Dynamics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.

### Abstract

**Background:** The test-negative design is an increasingly popular approach for estimating vaccine effectiveness (VE) due to its efficiency. This review aims to examine published test-negative design studies of VE and to explore similarities and differences in methodological choices for different diseases and vaccines.

---

**Corresponding author:** Prof. Benjamin J Cowling, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 7 Sassoon Road, Pokfulam, Hong Kong. Tel: +852 3917 6711; Fax: +852 3520 1945; bcowling@hku.hk.

POTENTIAL CONFLICTS OF INTEREST

BJC has received honoraria from Sanofi Pasteur and Roche. The authors report no other potential conflicts of interest.

**Methods:** We conducted a systematic search on PubMed, Web of Science, and Medline, for studies reporting the effectiveness of any vaccines using a test-negative design. We screened titles and abstracts, and reviewed full texts to identify relevant articles. We created a standardized form for each included article to extract information on the pathogen of interest, vaccine(s) being evaluated, study setting, clinical case definition, choices of cases and controls, and statistical approaches used to estimate VE.

**Results:** We identified a total of 348 articles, including studies on VE against influenza virus (n=253), rotavirus (n=48), pneumococcus (n=24), and nine other pathogens. Clinical case definitions used to enroll patients were similar by pathogens of interest but the sets of symptoms that defined them varied substantially. Controls could be those testing negative for the pathogen of interest, those testing positive for non-vaccine type of the pathogen of interest, or a subset of those testing positive for alternative pathogens. Most studies controlled for age, calendar time, and comorbidities.

**Conclusions:** Our review highlights similarities and differences in the application of the test-negative design that deserve further examination. If vaccination reduces disease severity in breakthrough infections, particular care must be taken in interpreting vaccine effectiveness estimates from test-negative design studies.

---

## INTRODUCTION

Vaccines have made major contributions to global health (1). While some vaccines confer strong life-long protection against infections, other vaccines provide more moderate or short-lived protection. Evolution in circulating pathogens can also modify vaccine effectiveness (VE), and some vaccines such as the influenza vaccine need to be updated regularly. Monitoring of VE to confirm continued effectiveness is an essential component of vaccination programmes (2). For reasons of ethics and logistics, observational studies rather than randomized trials are typically used to monitor VE post-licensure (3).

Case-control studies present a particularly efficient approach for monitoring VE because they tend to be faster and cheaper than cohort studies (4). A key design issue in case-control studies is the choice of controls, who should represent the exposure distribution in the source population from which the cases arose (5). Inappropriate control selection can lead to selection bias and, consequently, invalid conclusions (6). When cases have one particular infection or illness that is identified in a medical setting, controls can be selected from the general community, or from among patients with illnesses that are unlikely to be associated with both the disease and exposure of interest. For example, in a case-control study of cholera VE, cases might be selected from patients admitted to hospital with laboratory-confirmed cholera, while controls could be persons from the general community, or persons admitted to hospital with other diagnoses unrelated to cholera and no recent diarrhea or vomiting, to avoid potential misclassification of a case as a control (7).

In some situations, it is possible to draw a causal inference on the effect of particular exposures from observational studies. Because common factors may affect both the receipt of vaccination and the risk of infection, it is typically inappropriate to use the crude exposure odds ratio as a measure of the causal effect of the vaccine on the risk of disease. However, if

these confounding factors are taken into account, for example by statistical adjustment, given certain assumptions one minus the adjusted odds ratio can be used as an estimate of VE (8). Note that the VE is not a measure of the association between vaccination and infection status, but rather is a causal estimate of the effectiveness of the vaccine in preventing the disease. In case–control and test-negative design studies, we adjust the odds ratio for potential confounders, in order to estimate the causal effect of vaccination, i.e. the vaccine *effectiveness* (9, 10).

The “test-negative design” , in which the same clinical case definition is used for enrollment of both cases and controls, and laboratory testing is subsequently used to distinguish which patients were cases and which were controls, is increasingly used in VE studies (11). For example, patients with influenza-like illness could be enrolled in outpatient clinics, demographic information and influenza vaccination history obtained, and specimens collected for testing. Influenza VE can then be estimated by comparing influenza vaccination status in patients testing positive for influenza with those testing negative for influenza. In contrast to the traditional case–control design, controls in the test-negative design would meet the same clinical case definition as cases and are distinguished by laboratory testing results. An important advantage of this approach is the efficiency of enrolling cases and controls in the same location with the same case definition, thereby assuring that they have arisen from the same source population and reducing potential selection biases due to differential healthcare-seeking behavior (8). As with any case–control study, it is crucial to minimize false-positive cases (12) and so the laboratory test used must be highly specific (11, 13). While the test-negative design is typically presented as a variant of the case–control design (14), this study design can also be thought of as a variant of a cohort design where the entire population is the cohort, while the test-negative design includes only members for whom outcomes are ascertained (8, 15).

The test-negative design has been used under a number of different names for different vaccines. One of the earliest examples is the “indirect cohort” or Broome method. Broome *et al.* (16) showed that assuming pneumococcal vaccination did not affect the risk of non-vaccine-type pneumococcal infections among vaccinees (an assumption verified in early randomized controlled trials of polysaccharide vaccines (17, 18)), the odds of vaccination in those infected with non-vaccine-type and vaccine-type disease can be compared to estimate the effectiveness of pneumococcal vaccines. The widest application of the test-negative design has been for assessment of influenza VE, first done by Skowronski *et al.* in Canada, 2004/05 (19), and increasingly used since (11). The study design has been extended beyond vaccine studies, for example to identify risk factors for disease (20), and to improve the efficiency of cluster randomized intervention trials (21, 22). However, in this paper we focus only on vaccine studies.

Whether the application of the test-negative design for the study of VE against different pathogens is appropriate needs further evaluation, and the potential biases affecting VE estimates need to be ascertained within the context of the specific pathogen under study. The objectives of this study were therefore: to review published VE studies employing the test-negative design; to explore choices that have been made in the application of this design to

different vaccines; to explain the rationale for these choices; and to provide recommendations for the continued use of this approach to monitor VE.

## METHODS

### Search strategy and selection criteria

We followed the PRISMA guidelines in conducting this review. A systematic search was carried out on PubMed, Web of Science (WOS) and Medline, using the following terms on the 24 October 2018:

1. “vaccine” OR “vaccination”
2. “effectiveness” OR “efficacy”
3. #1 AND #2
4. #3 OR “VE”
5. “test-negative” OR “test negative” OR “TND” OR “indirect cohort” OR “quasi-cohort” OR “quasi cohort” OR “case–control” OR “case control” OR “case-referent” OR “case referent”
6. #4 AND #5

Articles published in any languages were considered. We also screened the reference lists of retrieved articles to identify any additional eligible studies.

### Screening

We first screened the list of titles returned from the search strategy to eliminate duplicates. HC and BJC independently screened all remaining titles. We defined test-negative design studies as those where all participants met the same clinical case definition (or the same set of syndromes), and cases and controls were discriminated by laboratory test results. Studies were eligible for inclusion if they reported results of a test-negative design to estimate the effectiveness of any type of vaccine for any pathogens in a defined population or population segment.

We excluded studies that did not use a test-negative design including randomized controlled trials (both conventional trials or trials that use the design to assess endpoints), prospective cohort studies, conventional case–control studies (defined as those enrolling controls not tested for the disease under study), studies that estimated VE using the screening method, and animal studies. We also excluded simulation studies, review articles, commentaries, letters, protocols, abstracts and book chapters. We excluded mid-season (interim) VE reports if they had been superseded by an end-of-season report and studies that re-analyzed data published by included studies. In the case where a study has been extended or followed up, we included only the more recent published article.

### Data extraction and analysis

Data were extracted from included articles using a standardized form in an electronic database created in REDCap (23). HC and SF independently extracted information on each

pathogen of interest, study setting, clinical case definition, choices of cases and controls, type(s) of vaccine being evaluated, and the statistical model used, including the variables included, to estimate VE.

A key characteristic of the test-negative design is the use of a control group with the same clinical presentation but testing negative for the pathogen of interest. This group of individuals may either be positive for alternative pathogens or negative for all pathogens (pan-negative or undiagnosed). As with any case-control study, the selection of controls should be made independently of exposure status to avoid selection bias. A situation where this assumption may be violated is the presence of viral interference, where vaccinated individuals may be more likely to be infected by alternative pathogens (24-26). Using such a group may inflate vaccination coverage among controls, misrepresenting the underlying population. While a meta-analysis showed no difference in VE estimates between choices of control groups among influenza VE studies, this is uncertain for non-influenza VE studies. It is also uncertain if the choice of non-vaccine type as controls is appropriate. We therefore categorized patients into six categories: tested-positive, vaccine type, non-vaccine type, tested-negative, alternative pathogens, and undiagnosed, according to the pathogen of interest and vaccine component (Table 1). To simplify comparisons between pathogens and vaccines, here the word “type” is used in a broad sense to refer also to subtype, genotype, serotype, species, subspecies, or strain of the pathogen of interest, depending on the specific pathogen (Table 1). If individuals were test-positive for the pathogen of interest, they may be further categorized as being matched to the vaccine type (i.e. tested-positive for a type that was a component of the vaccine) or non-vaccine type. For example, for pneumococcus, those serotypes covered by vaccine (PCV7, PCV10, PCV13, PCV14, PPV23) were defined as vaccine type and those not covered were defined as non-vaccine type. Similarly, when estimating influenza VE against influenza A(H1N1)pdm09 for the monovalent influenza A(H1N1)pdm09 vaccine in 2009/10, influenza subtype A(H1N1)pdm09 was defined as vaccine-type while pre-pandemic influenza A(H1N1), influenza A(H3N2) and influenza B were defined as non-vaccine type. If individuals were test-negative for the pathogen of interest, they may be categorized as positive for alternative pathogen (i.e. patients whose specimens tested positive for pathogen species other than the one of interest), or undiagnosed (i.e. patients whose specimens tested negative for all suspected pathogens).

## RESULTS

### Included studies

Our search on PubMed, Web of Science and Medline identified a total of 1976 unique articles, and we identified an additional 26 publications from reference lists of published articles. After screening, we identified 348 full text articles that met the criteria for inclusion in our review (Figure 1). We identified test-negative studies estimating VE for a total of 12 different pathogens, including influenza virus (n=253; inactivated=196; live-attenuated=2; both=28; unknown=27) (19, 27-275)(276-278), rotavirus (n=48; live-attenuated=48) (279-326), *Streptococcus pneumoniae* (n=24; conjugate=12; polysaccharide=12) (16, 327-349), *Bordetella pertussis* (n=6; toxoid=6) (350-355), *Vibrio cholerae* (n=4; inactivated=4) (356-359), poliovirus (n=4; live-attenuated=4) (360-363), *Neisseria*

*meningitidis* (n=3; conjugate=1; polysaccharide=2) (364-366), measles virus (n=2; live-attenuated=2) (367, 368), *Salmonella* Typhi (n=1; polysaccharide=1) (369), *Neisseria gonorrhoeae* (n=1; outer membrane vesicle=1) (370), human papillomavirus (HPV) (n=1; recombinant=1) (371), and *Haemophilus influenzae* (n=1; conjugate=1) (372). Figure 2 shows the number of test-negative design articles by type and year. The majority of the studies were published since 2010, and the earliest study that we identified was a study that estimated the effectiveness of pneumococcal vaccine published in 1980 (16).

### Settings and clinical criteria

Study populations were recruited from outpatient settings including emergency department (n=117), inpatients including those with short-stay (n=108), or both outpatient and inpatient settings (n=114) (Figure 3). Nine studies that did not specify patient recruitment settings were based on either statutory databases or laboratory-based surveillance systems. While influenza studies were often conducted in outpatient settings (45%), studies for other pathogens recruited mostly inpatients alone (e.g. 88% for pneumococcus) or both inpatients and outpatients (e.g. 58% for rotavirus).

The choices of case definition depended on the pathogen of interest (Table 2). For influenza studies, the commonly used clinical case definitions were influenza-like illness (n=143), acute respiratory infection for outpatients (n=47), severe acute respiratory infection for inpatients (n=9), febrile respiratory illness (n=4) and pneumonia (n=4). In eight studies, the above choices were not explicitly provided; study eligibility was nonetheless based on manifestation of systemic and/or respiratory symptoms (n=12). In 26 studies, any of the above-mentioned syndromes or influenza-associated complications were considered such as sepsis, exacerbation of underlying asthma, chronic obstructive pulmonary disease, stroke, etc.

We observed similarities across studies in the set of symptoms that defined these standard clinical case definitions (Figure 4). Most influenza studies included fever and various respiratory symptoms. Among 19 pneumococcus studies recruiting invasive pneumococcal disease patients, case definitions were based on laboratory test results detecting the pathogen in normally sterile sites (e.g. blood, cerebrospinal fluid) by culture (n=8) and various other tests (n=11) (Figure 4, panel B). Studies recruiting patients with pneumococcal pneumonia based the case definitions on radiologic findings as well as the presence of respiratory symptoms. Of 48 rotavirus studies that recruited patients with gastroenteritis, 21 considered occurrences of loose stools alone, 19 considered vomiting, and one dehydration besides loose stools, and seven studies did not clearly define gastroenteritis (Figure 4, panel C). None of the four *V. cholerae* studies adopting gastroenteritis as clinical case definition considered vomiting, but loose stools with (n=2) or without dehydration (n=2). Other studies (n=10) defined case definitions based on diagnostic test results or disease-specific symptoms, such as rash (measles virus, n=2) or acute paralytic illness (poliovirus, n=2). Occasionally, positive contact history were also considered (three influenza virus, one measles virus and one poliovirus studies).



## Classification of cases and controls

Specimens collected from patients who met case definitions were tested by various laboratory methods. Based on laboratory test results, the choices of cases and controls were divided into four categories: pathogen of vaccine type, non-vaccine type, alternative pathogens and undiagnosed (Figure 5, Table 1). The distinction of cases and controls varied substantially by pathogen of interest (Figure 5). Cases were defined as vaccine-type infections in 305 (88%) test-negative design studies focusing on influenza virus (n=253), pneumococcus, (n=23), rotavirus (n=10), *B. pertussis* (n=6), *V. cholerae* (n=4), poliovirus (n=4), *N. meningitidis* (n=3), HPV (n=1) and *H. influenzae* type b (n=1). Of 50 (15%) test-negative design studies that selected patients who tested-positive for the pathogen of interest (including both vaccine-type and non-vaccine-type strains) as cases, most were for rotavirus (n=47, 89%); in addition, three included patients with any pneumococcal strain, two addressed measles virus, and one addressed influenza virus.

We also identified 11 rotavirus studies assessing the effectiveness of vaccines against non-vaccine-type cases (Figure 5). These cases may include G9P or G12P if the vaccine assessed was pentavalent rotavirus vaccine (RV5), and may include G2P[4], G3P[8], G4P[8], G1P[8], G9P or G12P if the vaccine assessed was monovalent rotavirus vaccine (RV1) (Table 1). An unusual scenario was observed in a *N. gonorrhoeae* study where the effectiveness of outer membrane vesicle meningococcal B vaccine (MenZB) was evaluated. In this study, non-vaccine-type cases diagnosed positive for gonorrhoea were compared to controls diagnosed with *Chlamydia trachomatis*, an alternative pathogen.

Almost all influenza test-negative design studies (251/253, 99%) defined patients testing positive for influenza virus (i.e. vaccine-type) as cases and used patients who tested-negative for influenza as controls. Occasionally, patients who tested-positive for an alternative pathogen (n=15) or pan-negative (negative for all tested pathogen) (n=8) were also used as controls. Most of the non-influenza test-negative design studies (n=64, 67%) used all patients who tested negative for the vaccine pathogen as controls. These include studies of rotavirus (n=47), *V. cholerae* (n=4), poliovirus (n=4), pneumococcus (n=4), *B. pertussis* (n=2), measles virus (n=2) and HPV (n=1). We also identified five test-negative design studies (of *S. typhi*, rotavirus, *N. meningitidis*, *N. gonorrhoeae*, and *H. influenzae*) which defined controls as those diagnosed with alternative pathogens. An exception was observed for 21 (88%) pneumococcus, two *N. meningitidis* and one influenza virus studies, where patients infected by non-vaccine-type pathogens were used as controls for estimating VE. Undiagnosed patients were also chosen as the comparison group in four *B. pertussis* studies. In two pneumococcus studies, vaccine-type cases were compared to a control group consisting of both patients who tested-negative for pneumococcus and patients who tested-positive for non-vaccine-type pneumococcus.

## Approaches to estimation of VE

Age was the most commonly controlled variable (n=336, 97%) (Figure 6), as the probability of vaccination and the risk of infection can change with age. Studies controlled for the effect of age by adjustment in the statistical model (n=274, 79%), matching (n=29, 8%), restriction to particular age groups at the enrollment stage (n=19, 5%), or stratification (n=14, 4%). Up

to 83% (n=210) of influenza studies, 77% (n=37) of rotavirus studies, 50% (n=12) of pneumococcal studies, and 65% (n=15) of other studies adjusted for age in statistical model. A total of 10 (4%) influenza studies, two (8%) pneumococcal studies, one (17%) pertussis study, and one (33%) meningococcal study controlled for age by stratification. At the study design stage, 18 (7%) influenza studies, 8 (17%) rotavirus studies, two (50%) poliovirus studies, and one (4%) pneumococcal study matched cases and controls by age. Enrollment of study participants was restricted to particular age groups (<5, <18, 65) in seven (3%) influenza studies, five (21%) pneumococcal studies, three (6%) rotavirus studies, (50%) two poliovirus studies, one (17%) pertussis study, and one (100%) HPV study. Among studies that failed to control for age (n=12, 3%), three (25%) used other methods to examine the potential effect of age, such as by using stepwise regression (371).

How age was incorporated into VE models varied substantially, with most specifying a categorical variable (n=142, 52%; 132 were influenza studies). Age was also specified as a continuous variable in 46 (17%) studies. Of these, age was modeled using birth month alone (n=11) or along with birth year (n=9) as a continuous variable in rotavirus studies. A pneumococcal study and 24 influenza studies modeled age as a cubic spline variable. Other test-negative design studies failed to specify how age was modeled (n=57).

Calendar controlled for in 293 (84%) studies. The rationale for including this variable is that the probability of vaccination and risk of infection may change over time (8). Calendar time was most often controlled for by adjustment as a covariate in a statistical model (n=212/293, 72%), particularly in influenza virus studies (n=180, 71%). Adjustments were also made in 20 (42%) rotavirus studies, eight (33%) pneumococcal studies, one (25%) *V. cholerae* study, one (33%) meningococcal study, one (50%) measles virus study, and one (100%) *S. Typhi* study. We also identified three (1%) influenza virus studies, three (50%) pertussis studies and one (2%) rotavirus study which conducted time-stratified analyses, 34 (13%) influenza virus studies, four (8%) rotavirus, one (4%) pneumococcus study, one (25%) poliovirus study, and one (17%) pertussis study matched cases and controls by calendar time, while 27 (11%) influenza studies, five (10%) rotavirus studies, and one (25%) *V. cholerae* study also controlled for time by restricting patient recruitment to epidemic periods.

Among studies that controlled for the effect of time, calendar time was commonly modeled using week (n=76), month (n=72) and 2-weeks interval (n=25). Studies modeling time using week (n=43), month (n=63) or 2-weeks interval (n=6) often did not specify how these time units were modeled. Wherever this information was available, week was most commonly modeled as a matching (n=13), spline (n=11), categorical (n=5), or continuous variable (n=4); month was modeled as a categorical (n=4), matching (n=3), or stratifying variable (n=2); while 2-weeks interval was modeled as a matching (n=10) or categorical variable (n=9). Three studies used 15-days (n=1), 2-months (n=1), or 3-months intervals (n=1) as a matching variable. Two studies controlled for time using 3 weeks without specifying how these were modeled. Occasionally, timing of symptom onset was modeled as a cubic spline (n=6) or matching variable (n=2), time of presentation was modeled as a matching (n=4), cubic spline (n=1) or continuous (n=1) variable, and time since study began was modeled as a cubic spline (n=1) variable. Studies that covered a time period over more than one season also controlled for the effect of calendar time by stratification or adjusting for season (n=19)



or year (n=12). In the remaining 36 studies, it was unclear what time intervals were used or how time was modeled.

Around half of all eligible studies controlled for comorbidities (n=187, 54%) and sex (n=150, 43%). A total of 40 (21%) also considered obesity and 26 (14%) considered pregnancy. We identified a total of 50 influenza studies that controlled for previous vaccination in their statistical models. Prior infection was not commonly examined; however, we identified five studies that considered prior infection by statistical adjustment (n=4) or restriction (n=1) (167, 218, 240, 254, 273). The majority of studies (n=236) controlled for time intervals from disease onset to laboratory testing. Among these, 53 (22.5%) used statistical adjustment while the remainder used restriction to delays of one week or less (n=144, 61%), two weeks or less (n=36, 15.3%) or one month or less (n=3, 1.3%).

## DISCUSSION

We identified and reviewed the methodologic approaches of 348 published test-negative design studies for 12 different pathogens. We identified a rapid increase in the use of the test-negative design for studying VE in recent years, with 90% of studies published since 2011 (Figure 2). Studies share a number of similarities. Case definitions and study sites were generally similar between studies examining the same pathogen. Approaches to the distinction between cases and controls were mostly consistent among studies of the same pathogen, but differed among pathogens (Figure 5). We identified common covariates included in statistical models to estimate VE, i.e. age, calendar time, sex, and comorbidities, but the way covariates were controlled for varied between studies of different and same pathogens.

Potential limitations of the test-negative design study have previously been discussed and examined by a number of authors (8, 13, 373-378). Simulation studies have shown that biases may arise under several circumstances, including if the study fails to adjust for calendar time (373), if vaccination affects the probability of non-influenza infections (374), if vaccination affects the probability of seeking care between cases and controls (375, 376), if healthcare-seeking behavior differs substantially between cases and controls (377), and if misclassification bias is present (13, 378). The ability of the test-negative design to recover accurate VE estimates under a scenario of “leaky” protection has also been questioned (381), although similar biases may be present under other designs as well (3).

The test-negative design is convenient and efficient, and therefore it has been readily applied to laboratory-based surveillance data and health management data as observed in the studies of *B. pertussis* (351-353), and sometimes with linkage data to obtain vaccination or infection status. However, the importance of clear and specific case definitions should not be overlooked, and prospective test-negative design studies may be the most robust. An important strength of the study design is that, in selecting a group of patients who seek care for specific syndromes, it increases similarity between cases and controls, thus minimizing selection bias. One of the potential limitations of using administrative data for the test-

negative design is that it may not always be clear if patients who were tested actually met the case definition.

The choices of study settings for test-negative design studies depended on the diseases of interest, disease severity, and vaccines. Pneumococcal vaccines were licensed primarily for prevention of severe infection leading to hospitalization (379), in contrast to other vaccines such as rotavirus vaccine and oral cholera vaccine that were recommended as part of a comprehensive strategy of disease control (380). Therefore, patients in pneumococcal VE studies frequently consisted of those severely ill and hospitalized with invasive pneumococcal disease or community-acquired pneumonia. Conversely, for studies of influenza or rotavirus VE, for example, disease outcomes may consist of a broader spectrum of diseases from mild to severe, and patients may be recruited from both inpatient or outpatient settings. Biases could persist under the test-negative design if broad variation in disease manifestation gives rise to differential healthcare-seeking behavior in terms of vaccination and care seeking for symptoms, and affect the probability of being tested (381). A more stringent clinical case definition could be used to reduce this source of bias, for example by recruiting severely ill inpatients as in the case of pneumococcus (381). Because disease severity could vary by setting, it is important to consider carefully the most appropriate setting to monitor VE, and in general it may not be appropriate to pool data from inpatients and outpatients when estimating VE.

There was some variation in the clinical case definitions used to recruit study participants. For example, the definitions for influenza-like illness may or may not include myalgia, definitions for gastroenteritis may include loose stools with or without vomiting. It is not clear if the sensitivity of clinical case criteria biases VE estimates, but modeling studies could provide further insight. The theoretical model shows that although more stringent clinical case definitions are, by definition, less sensitive, less biased VE estimates can be obtained. This may be because health-care seeking is highly likely among individuals with severe presentations, reducing the potential for differential health-care seeking between vaccinated and unvaccinated persons (381). Because the choice of clinical case criteria may depend on healthcare seeking behaviors of the specific population being studied (382), standardizing case definitions across all settings may not be feasible. Nevertheless, the choice of clinical symptoms for enrolled patients should ensure similarity between cases and controls and not be dependent on the vaccination or important confounders of the vaccination-disease relationship. An important consideration, therefore, in the application of the test-negative design is whether the vaccine in question causes there to be a difference in the source populations from which the cases and controls are derived. For example, in the case of rotavirus vaccine, where vaccination can mitigate the severity of disease, the propensity to seek care differs between cases and controls leading to a form of selection (collider) bias that can harm the validity of VE estimates (8, 381). The test-negative design should not therefore be blindly applied to all vaccine-preventable diseases; valid application must consider the biological mechanisms underlying the vaccine's effectiveness.

In terms of distinguishing cases from controls, most studies defined vaccine-type as cases, where vaccines being evaluated were believed to have protective effect against the strains included in the vaccine. In the scenario where vaccination is thought to provide cross-

protection against non-vaccine-types of the same pathogen, for example in rotavirus studies, cases also included non-vaccine-types or all patients testing positive for the pathogen regardless of type. We also identified a lack of consensus on the choices of controls for each vaccine (Figure 5). We would be particularly cautious over the choice of non-vaccine-type patients as controls for vaccine-type cases, as observed in most of the pneumococcal studies. The reason for this is twofold. First, cross-protection may occur (383-385): Some studies have reported a decline in non-vaccine-type pneumococcal disease progression after vaccine rollout leading to the hypothesis that vaccination may have a secondary effect in preventing non-vaccine-type disease even from serotypes against which no cross-protection is expected (386-388). Second, a basic assumption of the test-negative design is that the risk of infections by non-vaccine-targeted causative pathogens resulting in similar clinical disease does not vary by vaccination status. This assumption may be violated in pneumococcal studies if there is a serotype replacement phenomenon, i.e. an increase in the incidence or proportions of infections caused by non-vaccine-types following vaccine introduction (389). It has been argued that the impact of serotype replacement is minimal compared to the substantial reduction observed in overall invasive pneumococcal disease following vaccination (389, 390). Studies also showed that the magnitude for serotype replacement-associated bias in VE estimated by the indirect cohort method is likely to be small in practice (327). The choice to include vaccine-matched pathogens or not should therefore depend on the public health question to be answered: are we interested in knowing by how much this vaccine will reduce the burden of the clinical disease of interest? Or are we interested in estimating the effectiveness of the vaccine only with respect to the pathogens it specifically targets. From a programmatic, policy and public health perspective the former argument is perhaps more relevant.

Notwithstanding the public health intent of a VE study, measuring vaccine effectiveness implies the intention to assess the strength of a causal effect of vaccination on risk of disease (10). Given that test-negative design studies are observational in nature, causal estimates could be biased due to confounding, underscoring the importance of adequate confounder control. Almost all studies controlled for some potential confounders by adjustment, matching, stratification, or restriction. Age is a common confounder as it is likely to be associated with the odds of being vaccinated (exposure) and infected (outcome). Therefore, almost all VE studies should control for age. How this was done was inconsistent across studies and it is unclear by how much the variation in variable specification can harm estimates. However, categorization of a continuous variable will lead to residual confounding, the importance of which matters in VE studies more when small changes in age correspond to large differences in immunological competence. Calendar time was controlled for in studies spanning several years or diseases that manifest seasonal trends, for example influenza virus and rotavirus. Controlling for calendar time is important in situations when vaccination uptake and risk of disease vary over time. Studies have postulated that VE estimates can be biased when controls are recruited outside of the influenza season because vaccination coverage may not reflect coverage during the influenza season (373, 391). Controlling for calendar time or age is also important when investigating the effect of age or time on waning or persistence of vaccine-induced immunity, particularly for immunization programs targeting specific age groups, e.g. childhood vaccines (381).

Where stratified estimates by age or time periods are provided, meaningful interpretation of stratified estimates requires understanding of the mechanism of vaccine under study, whether vaccine confers protection to a proportion of those vaccinated or reduces the force of infection in those unvaccinated (392). In the latter scenario, a decrease in VE might be truly due to a decline over time in protection, or an artefact of depletion of unvaccinated susceptibles (381, 393). It has also been shown that estimation of VE in the test-negative design requires that vaccine confers “all-or-nothing” protection to those vaccinated, but whether vaccine is “all-or-nothing” or “leaky” is not often known (381).

This systematic review extended previous test-negative design reviews and provided a more comprehensive review of the application of the study design in studying VE (11). For some pathogens, studies were too limited to make a fair evaluation of the appropriateness of the test-negative design. We also treated all studies as equal including mid-season (interim) reports for influenza VE which could be reported less meticulously compared to end-of-season reports. Our inclusion criteria were restricted to studies which distinguished case–control status based on laboratory-confirmed presence or absence of the pathogen of interest. We therefore excluded studies by Crowe *et al.* and Muganga *et al.* which assessed the effectiveness of HPV vaccine on histology-based outcomes, and the effectiveness of Hib on purulent cerebrospinal fluid meningitis respectively (394, 395). While these studies can be considered as variants of the test-negative design, there was not a specific definition for the choice of cases. We also excluded studies that used the test-negative design approach to examine bias and confounders (396). One other notable excluded set of studies were randomized controlled trials of adenovirus vaccine conducted in the 1960s, which used a nested test-negative style analysis to estimate VE (397-399).

The test-negative design serves as an efficient option to estimate the effectiveness of vaccines against various diseases and its use is likely to increase in the near future with the introduction of new vaccines and the re-emergence of vaccine-preventable diseases. Based on our findings, we provided several practical recommendations on the applications of the test-negative design to non-influenza pathogens (Box 1). In the case where vaccination reduces disease severity, application of the test-negative design should not be recommended. Careful consideration should therefore be taken into account before applying the test-negative design to estimate VE. Moving forward, given the prospect of increasing use of the study design for multiple diseases, we would like to introduce the idea of establishing a general test-negative design “platform” to facilitate timely VE estimates. For example, all new pediatric admissions (or a chosen subset) could be assessed against a number of clinical case definitions, tested for relevant pathogens consistent with signs/symptoms, and their vaccine history determined, so that those with influenza-like illness could contribute to monitoring VE for influenza (and, in due course, respiratory syncytial virus), those with fever and rash could contribute to monitoring varicella, measles, or enterovirus EV-A71 VE, etc. Besides facilitating annual surveillance of influenza VE, such a platform could help better planning of public health responses in the event of, for example, the reemergence of measles which requires re-evaluation of the effectiveness of measles-containing vaccines (400). Using a platform approach could be an efficient approach to monitor VE for a range of vaccines on an ongoing basis. Once established, such a platform would also be ideal for timely monitoring of vaccines against emerging or re-emerging infections.

## ACKNOWLEDGMENTS

We thank Julie Au for administrative support.

### FUNDING

This work was supported by a commissioned grant from the Health and Medical Research Fund of the Food and Health Bureau of Hong Kong, and the Research Grants Council of the Hong Kong Special Administrative Region (project no. T11-705/14N). ML and BJC are supported by the Harvard Center for Communicable Disease Dynamics from the National Institute of General Medical Sciences (grant no. U54 GM088558). The WHO Collaborating Centre for Reference and Research on Influenza is supported by the Australian Government Department of Health. The funding bodies had no role in study design, data collection and analysis, preparation of the manuscript, or the decision to publish.

## REFERENCES

- Greenwood B The contribution of vaccination to global health: past, present and future. *Philos Trans R Soc Lond B Biol Sci.* 2014;369(1645):20130433. [PubMed: 24821919]
- Derrough T, Olsson K, Gianfredi V, Simondon F, Heijbel H, Danielsson N, et al. Immunisation Information Systems - useful tools for monitoring vaccination programmes in EU/EEA countries, 2016. *Euro Surveill.* 2017;22(17):pii=30519.
- Smith PG, Rodrigues LC, Fine PE. Assessment of the protective efficacy of vaccines against common diseases using case-control and cohort studies. *Int J Epidemiol.* 1984;13(1):87-93. [PubMed: 6698708]
- Verani JR, Baqui AH, Broome CV, Cherian T, Cohen C, Farrar JL, et al. Case-control vaccine effectiveness studies: Data collection, analysis and reporting results. *Vaccine.* 2017;35(25):3303-8. [PubMed: 28442230]
- Wacholder S, McLaughlin JK, Silverman DT, Mandel JS. Selection of controls in case-control studies. I. Principles. *Am J Epidemiol.* 1992;135(9):1019-28. [PubMed: 1595688]
- Berkson J Limitations of the application of fourfold table analysis to hospital data. *Biometrics.* 1946;2(3):47-53. [PubMed: 21001024]
- Verani JR, Baqui AH, Broome CV, Cherian T, Cohen C, Farrar JL, et al. Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls. *Vaccine.* 2017;35(25):3295-302. [PubMed: 28442231]
- Sullivan SG, Tchetgen Tchetgen EJ, Cowling BJ. Theoretical Basis of the Test-Negative Study Design for Assessment of Influenza Vaccine Effectiveness. *Am J Epidemiol.* 2016;184(5):345-53. [PubMed: 27587721]
- Cowling BJ, Sullivan SG. A concern over terminology in vaccine effectiveness studies. *Euro Surveill.* 2018;23(10):pii=18-00103.
- Sullivan SG, Cowling BJ. "Crude Vaccine Effectiveness" Is a Misleading Term in Test-negative Studies of Influenza Vaccine Effectiveness. *Epidemiology.* 2015;26(5):e60. [PubMed: 26133018]
- Sullivan SG, Feng S, Cowling BJ. Potential of the test-negative design for measuring influenza vaccine effectiveness: a systematic review. *Expert Rev Vaccines.* 2014;13(12):1571-91. [PubMed: 25348015]
- Rothman KJ, Greenland S, Lash TL. *Modern Epidemiology.* 3rd ed: Lippincott Williams & Wilkins; 2008.
- Jackson ML, Rothman KJ. Effects of imperfect test sensitivity and specificity on observational studies of influenza vaccine effectiveness. *Vaccine.* 2015;33(11):1313-6. [PubMed: 25659280]
- De Serres G, Skowronski DM, Wu XW, Ambrose CS. The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials. *Euro Surveill.* 2013;18(37):pii=20585.
- Lipsitch M, Jha A, Simonsen L. Observational studies and the difficult quest for causality: lessons from vaccine effectiveness and impact studies. *Int J Epidemiol.* 2016;45(6):2060-74. [PubMed: 27453361]

16. Broome CV, Facklam RR, Fraser DW. Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine. *N Engl J Med.* 1980;303(10): 549–52. [PubMed: 6995835]
17. Ekwurzel GM, Simmons JS, Dublin LI, Felton LD. Studies on immunizing substances in pneumococci. VIII. Report on field tests to determine the prophylactic value of a pneumococcus antigen. *Public Health Rep.* 1938;53(42):1877–93.
18. Macleod CM, Hodges RG, Heidelberger M, Bernhard WG. Prevention of Pneumococcal Pneumonia by Immunization with Specific Capsular Polysaccharides. *J Exp Med.* 1945;82(6): 445–65.
19. Skowronski Dea. Effectiveness of vaccine against medical consultation due to laboratory-confirmed influenza: results from a sentinel physician pilot project in British Columbia, 2004–2005. *Can Commun Dis Rep.* 2005;31(18):181–91. [PubMed: 16669132]
20. Yung CF, Chan SP, Thein TL, Chai SC, Leo YS. Epidemiological risk factors for adult dengue in Singapore: an 8-year nested test negative case control study. *BMC Infect Dis.* 2016;16:323. [PubMed: 27390842]
21. Anders KL, Cutcher Z, Kleinschmidt I, Donnelly CA, Ferguson NM, Indriani C, et al. Cluster Randomized Test-Negative Design (CR-TND) Trials: A Novel and Efficient Method to Assess the Efficacy of Community Level Dengue Interventions. *Am J Epidemiol.* 2018;187(9):2021–8. [PubMed: 29741576]
22. Jewell NP, Dufault S, Cutcher Z, Simmons CP, Anders KL. Analysis of cluster-randomized test-negative designs: cluster-level methods. *Biostatistics.* 2018 (in press).
23. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform.* 2009;42(2):377–81. [PubMed: 18929686]
24. Cowling BJ, Nishiura H. Virus interference and estimates of influenza vaccine effectiveness from test-negative studies. *Epidemiology.* 2012;23(6):930–1. [PubMed: 23038121]
25. Feng S, Cowling BJ, Kelly H, Sullivan SG. Estimating Influenza Vaccine Effectiveness in the Test-negative Design Using Alternative Control Groups - a Systematic Review and Meta-analysis. *Am J Epidemiol.* 2017.
26. Cowling BJ, Fang VJ, Nishiura H, Chan KH, Ng S, Ip DK, et al. Increased risk of noninfluenza respiratory virus infections associated with receipt of inactivated influenza vaccine. *Clin Infect Dis.* 2012;54(12):1778–83. [PubMed: 22423139]
27. Amour S, Voirin N, Regis C, Bouscambert-Duchamp M, Comte B, Coppere B, et al. Influenza vaccine effectiveness among adult patients in a University of Lyon hospital (2004–2009). *Vaccine.* 2012;30(5):821–4. [PubMed: 22138212]
28. Andrews N, Waight P, Yung C-F, Miller E. Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. *J Infect Dis.* 2011;203(1):32–9. [PubMed: 21148494]
29. Andrews N, McMenamin J, Durnall H, Ellis J, Lackenby A, Robertson C, et al. Effectiveness of trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2012/13 end of season results. *Euro Surveill.* 2014;19(27):5–13.
30. Barret AS, Donnell JO, O’Hora A, Collins C, Coughlan S, Joyce M, et al. Effectiveness of 2010/2011 seasonal influenza vaccine in Ireland. *Ir Med J.* 2012;105(2):39–42. [PubMed: 22455236]
31. Bateman AC, Kieke BA, Irving SA, Meece JK, Shay DK, Belongia EA. Effectiveness of monovalent 2009 pandemic influenza A virus subtype H1N1 and 2010–2011 trivalent inactivated influenza vaccines in Wisconsin during the 2010–2011 influenza season. *J Infect Dis.* 2013;207(8): 1262–9. [PubMed: 23341536]
32. Belongia EA, Kieke BA, Donahue JG, Greenlee RT, Balish A, Foust A, et al. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004–2005 season to the 2006–2007 season. *J Infect Dis.* 2009;199(2):159–67. [PubMed: 19086915]
33. Belongia EA, Kieke BA, Donahue JG, Coleman LA, Irving SA, Meece JK, et al. Influenza vaccine effectiveness in Wisconsin during the 2007–08 season: comparison of interim and final results. *Vaccine.* 2011;29(38):6558–63. [PubMed: 21767593]



34. Blyth CC, Jacoby P, Effler PV, Kelly H, Smith DW, Robins C, et al. Effectiveness of trivalent flu vaccine in healthy young children. *Pediatrics*. 2014;133(5):e1218–25. [PubMed: 24753525]
35. Coleman LA, Kieke B, Irving S, Shay DK, Vandermause M, Lindstrom S, et al. Comparison of influenza vaccine effectiveness using different methods of case detection: clinician-ordered rapid antigen tests vs. active surveillance and testing with real-time reverse-transcriptase polymerase chain reaction (rRT-PCR). *Vaccine*. 2011;29(3):387–90. [PubMed: 21095253]
36. Castilla J, Moran J, Martinez-Artola V, Fernandez-Alonso M, Guevara M, Cenoz MG, et al. Effectiveness of the monovalent influenza A(H1N1)2009 vaccine in Navarre, Spain, 2009–2010: cohort and case–control study. *Vaccine*. 2011;29(35):5919–24. [PubMed: 21723358]
37. Castilla J, Martinez-Artola V, Salcedo E, Martinez-Baz I, Cenoz MG, Guevara M, et al. Vaccine effectiveness in preventing influenza hospitalizations in Navarre, Spain, 2010–2011: cohort and case–control study. *Vaccine*. 2012;30(2):195–200. [PubMed: 22100636]
38. Castilla J, Martinez-Baz I, Martinez-Artola V, Reina G, Pozo F, Garcia Cenoz M, et al. Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. *Euro Surveill*. 2013;18(5):pii=20388.
39. Cheng AC, Kotsimpos T, Kelly HA, Irving LB, Bowler SD, Brown SG, et al. Effectiveness of H1N1/09 monovalent and trivalent influenza vaccines against hospitalization with laboratory-confirmed H1N1/09 influenza in Australia: a test-negative case control study. *Vaccine*. 2011;29(43):7320–5. [PubMed: 21810450]
40. Cheng AC, Holmes M, Irving LB, Brown SG, Waterer GW, Korman TM, et al. Influenza vaccine effectiveness against hospitalisation with confirmed influenza in the 2010–11 seasons: a test-negative observational study. *PLoS One*. 2013;8(7):e68760. [PubMed: 23874754]
41. Cowling BJ, Chan KH, Feng S, Chan EL, Lo JY, Peiris JS, et al. The effectiveness of influenza vaccination in preventing hospitalizations in children in Hong Kong, 2009–2013. *Vaccine*. 2014;32(41):5278–84. [PubMed: 25092636]
42. Dawood FS, Prapasiri P, Areerat P, Ruayajin A, Chittaganpitch M, Muangchana C, et al. Effectiveness of the 2010 and 2011 Southern Hemisphere trivalent inactivated influenza vaccines against hospitalization with influenza-associated acute respiratory infection among Thai adults aged  $\geq 50$  years. *Influenza Other Respir Viruses*. 2014;8(4):463–8. [PubMed: 24490684]
43. Eick-Cost AA, Tastad KJ, Guerrero AC, Johns MC, Lee SE, Macintosh VH, et al. Effectiveness of seasonal influenza vaccines against influenza-associated illnesses among US military personnel in 2010–11: a case–control approach. *PLoS One*. 2012;7(7):e41435. [PubMed: 22859985]
44. Eisenberg KW, Szilagyi PG, Fairbrother G, Griffin MR, Staat M, Shone LP, et al. Vaccine effectiveness against laboratory-confirmed influenza in children 6 to 59 months of age during the 2003–2004 and 2004–2005 influenza seasons. *Pediatrics*. 2008;122(5):911–9. [PubMed: 18977968]
45. Englund H, Campe H, Hautmann W. Effectiveness of trivalent and monovalent influenza vaccines against laboratory-confirmed influenza infection in persons with medically attended influenza-like illness in Bavaria, Germany, 2010/2011 season. *Epidemiol Infect*. 2013;141(9):1807–15. [PubMed: 23098364]
46. Ferdinands JM, Olsho LE, Agan AA, Bhat N, Sullivan RM, Hall M, et al. Effectiveness of influenza vaccine against life-threatening RT-PCR-confirmed influenza illness in US children, 2010–2012. *J Infect Dis*. 2014;210(5):674–83. [PubMed: 24676207]
47. Fielding JE, Grant KA, Papadakis G, Kelly HA. Estimation of type- and subtype-specific influenza vaccine effectiveness in Victoria, Australia using a test negative case control method, 2007–2008. *BMC Infect Dis*. 2011;11:170. [PubMed: 21669006]
48. Fielding JE, Grant KA, Garcia K, Kelly HA. Effectiveness of seasonal influenza vaccine against pandemic (H1N1) 2009 virus, Australia, 2010. *Emerg Infect Dis*. 2011;17(7):1181–7. [PubMed: 21762570]
49. Fielding JE, Grant KA, Tran T, Kelly HA. Moderate influenza vaccine effectiveness in Victoria, Australia, 2011. *Euro Surveill*. 2012;17(11):pii=20115.
50. Fleming DM, Andrews NJ, Ellis J, Bermingham A, Sebastian Pillai P, Elliot AJ, et al. Estimating influenza vaccine effectiveness using routinely collected laboratory data. *J Epidemiol Community Health*. 2010;64(12):1062–7. [PubMed: 19910645]

51. Gefenaite G, Rahamat-Langendoen J, Ambrozaitis A, Mickiene A, Jancoriene L, Kuliese M, et al. Seasonal influenza vaccine effectiveness against influenza in 2012–2013: a hospital-based case–control study in Lithuania. *Vaccine*. 2014;32(7):857–63. [PubMed: 24370711]
52. Griffin MR, Monto AS, Belongia EA, Treanor JJ, Chen Q, Chen J, et al. Effectiveness of non-adjuvanted pandemic influenza A vaccines for preventing pandemic influenza acute respiratory illness visits in 4 U.S. communities. *PLoS One*. 2011;6(8):e23085. [PubMed: 21857999]
53. Hardelid P, Fleming DM, McMenamin J, Andrews N, Robertson C, Sebastian Pillai P, et al. Effectiveness of pandemic and seasonal influenza vaccine in preventing pandemic influenza A(H1N1)2009 infection in England and Scotland 2009–2010. *Euro Surveill*. 2011;16(2):pii=19763.
54. Hellenbrand W, Jorgensen P, Schweiger B, Falkenhorst G, Nachtnebel M, Greutelaers B, et al. Prospective hospital-based case–control study to assess the effectiveness of pandemic influenza A(H1N1)pdm09 vaccination and risk factors for hospitalization in 2009–2010 using matched hospital and test-negative controls. *BMC Infect Dis*. 2012;12:127. [PubMed: 22650369]
55. Ho HP, Zhao X, Pang J, Chen MI, Lee VJ, Ang LW, et al. Effectiveness of seasonal influenza vaccinations against laboratory-confirmed influenza-associated infections among Singapore military personnel in 2010–2013. *Influenza Other Respir Viruses*. 2014;8(5):557–66. [PubMed: 24828687]
56. Janjua NZ, Skowronski DM, De Serres G, Dickinson J, Crowcroft NS, Taylor M, et al. Estimates of influenza vaccine effectiveness for 2007–2008 from Canada’s sentinel surveillance system: cross-protection against major and minor variants. *J Infect Dis*. 2012;205(12):1858–68. [PubMed: 22492921]
57. Jefferies S, Earl D, Berry N, Blackmore T, Rooker S, Raymond N, et al. Effectiveness of the 2009 seasonal influenza vaccine against pandemic influenza A (H1N1) 2009 in healthcare workers in New Zealand, June–August 2009. *Euro Surveill*. 2011;16(2):pii=19761.
58. Jimenez-Jorge S, Savulescu C, Pozo F, de Mateo S, Casas I, Ledesma J, et al. Effectiveness of the 2010–11 seasonal trivalent influenza vaccine in Spain: cycEVA study. *Vaccine*. 2012;30(24):3595–602. [PubMed: 22472792]
59. Jiménez-Jorge S, de Mateo S, Delgado-Sanz C, Pozo F, Casas I, Garcia-Cenoz M, et al. Effectiveness of influenza vaccine against laboratory-confirmed influenza, in the late 2011–2012 season in Spain, among population targeted for vaccination. *BMC Infect Dis*. 2013;13(1):441. [PubMed: 24053661]
60. Kafatos G, Pebody R, Andrews N, Durnall H, Barley M, Fleming D. Effectiveness of seasonal influenza vaccine in preventing medically attended influenza infection in England and Wales during the 2010/2011 season: a primary care-based cohort study. *Influenza Other Respir Viruses*. 2013;7(6):1175–80. [PubMed: 24103037]
61. Kelly H, Carville K, Grant K, Jacoby P, Tran T, Barr I. Estimation of influenza vaccine effectiveness from routine surveillance data. *PLoS One*. 2009;4(3):e5079. [PubMed: 19333374]
62. Kelly HA, Grant KA, Fielding JE, Carville KS, Looker CO, Tran T, et al. Pandemic influenza H1N1 2009 infection in Victoria, Australia: no evidence for harm or benefit following receipt of seasonal influenza vaccine in 2009. *Vaccine*. 2011;29(37):6419–26. [PubMed: 21473950]
63. Kelly H, Jacoby P, Dixon GA, Carcione D, Williams S, Moore HC, et al. Vaccine Effectiveness Against Laboratory-confirmed Influenza in Healthy Young Children: A Case–control Study. *Pediatr Infect Dis J*. 2011;30(2):107–11. [PubMed: 21079528]
64. Kissling E, Valenciano M, Falcao J, Larrauri A, Widgren K, Pitigoi D, et al. “I-MOVE” towards monitoring seasonal and pandemic influenza vaccine effectiveness: lessons learnt from a pilot multi-centric case–control study in Europe, 2008–9. *Euro Surveill*. 2009;14(44):pii=19388.
65. Kissling E, Valenciano M, Cohen JM, Oroszi B, Barret AS, Rizzo C, et al. I-MOVE multi-centre case control study 2010–11: overall and stratified estimates of influenza vaccine effectiveness in Europe. *PLoS One*. 2011;6(11):e27622. [PubMed: 22110695]
66. Kissling E, Valenciano M, Larrauri A, Oroszi B, Cohen JM, Nunes B, et al. Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case–control study. *Euro Surveill*. 2013;18(5):pii=20390.

67. Kissling E, Valenciano M, Buchholz U, Larrauri A, Cohen JM, Nunes B, et al. Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case-control study, influenza season 2012/13. *Euro Surveill.* 2014;19(6):pii=20701.
68. Kwong JC, Campitelli MA, Gubbay JB, Peci A, Winter AL, Olsha R, et al. Vaccine effectiveness against laboratory-confirmed influenza hospitalizations among elderly adults during the 2010–2011 season. *Clin Infect Dis.* 2013;57(6):820–7. [PubMed: 23788243]
69. Larrauri A, Savulescu C, Jimenez-Jorge S, Perez-Brena P, Pozo F, Casas I, et al. Influenza pandemic (H1N1) 2009 activity during summer 2009. Effectiveness of the 2008–9 trivalent vaccine against pandemic influenza in Spain. *Gac Sanit.* 2011;25(1):23–8. [PubMed: 21334788]
70. Lo YC, Chuang JH, Kuo HW, Huang WT, Hsu YF, Liu MT, et al. Surveillance and vaccine effectiveness of an influenza epidemic predominated by vaccine-mismatched influenza B/Yamagata-lineage viruses in Taiwan, 2011–12 season. *PLoS One.* 2013;8(3):e58222. [PubMed: 23472161]
71. Mahmud S, Hammond G, Elliott L, Hilderman T, Kurbis C, Caetano P, et al. Effectiveness of the pandemic H1N1 influenza vaccines against laboratory-confirmed H1N1 infections: population-based case-control study. *Vaccine.* 2011;29(45):7975–81. [PubMed: 21884747]
72. Mahmud SM, Van Caesele P, Hammond G, Kurbis C, Hilderman T, Elliott L. No association between 2008–09 influenza vaccine and influenza A (H1N1) pdm09 virus infection, Manitoba, Canada, 2009. *Emerg Infect Dis.* 2012;18(5):801. [PubMed: 22516189]
73. Martinez-Baz I, Martinez-Artola V, Reina G, Guevara M, Cenoz MG, Moran J, et al. Effectiveness of the trivalent influenza vaccine in Navarre, Spain, 2010–2011: a population-based test-negative case-control study. *BMC Public Health.* 2013;13:191. [PubMed: 23496887]
74. Menniti-Ippolito F, Da Cas R, Traversa G, Santuccio C, Felicetti P, Tartaglia L, et al. Vaccine effectiveness against severe laboratory-confirmed influenza in children: results of two consecutive seasons in Italy. *Vaccine.* 2014;32(35):4466–70. [PubMed: 24962760]
75. Nunes B, Machado A, Guiomar R, Pechirra P, Conde P, Cristovao P, et al. Estimates of 2012/13 influenza vaccine effectiveness using the case test-negative control design with different influenza negative control groups. *Vaccine.* 2014;32(35):4443–9. [PubMed: 24962756]
76. Ohmit SE, Thompson MG, Petrie JG, Thaker SN, Jackson ML, Belongia EA, et al. Influenza vaccine effectiveness in the 2011–2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. *Clin Infect Dis.* 2014;58(3):319–27. [PubMed: 24235265]
77. Ortqvist A, Bennet R, Rinder MR, Lindblad H, Eriksson M. Effectiveness of the monovalent AS03-adjuvanted influenza A(H1N1)pdm09 vaccine against hospitalization in children because of influenza. *Vaccine.* 2012;30(39):5699–702. [PubMed: 22819987]
78. Pebody R, Andrews N, Waight P, Malkani R, McCartney C, Ellis J, et al. No effect of 2008/09 seasonal influenza vaccination on the risk of pandemic H1N1 2009 influenza infection in England. *Vaccine.* 2011;29(14):2613–8. [PubMed: 21292008]
79. Pebody RG, Andrews N, Fleming DM, McMenamin J, Cottrell S, Smyth B, et al. Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom. *Epidemiol Infect.* 2013;141(3):620–30. [PubMed: 22691710]
80. Pebody R, Andrews N, McMenamin J, Durnall H, Ellis J, Thompson CI, et al. Vaccine effectiveness of 2011/12 trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: evidence of waning intra-seasonal protection. *Euro Surveill.* 2013;18(5):pii=20389.
81. Puig-Barbera J, Arnedo-Pena A, Pardo-Serrano F, Tirado-Balaguer MD, Perez-Vilar S, Silvestre-Silvestre E, et al. Effectiveness of seasonal 2008–2009, 2009–2010 and pandemic vaccines, to prevent influenza hospitalizations during the autumn 2009 influenza pandemic wave in Castellon, Spain. A test-negative, hospital-based, case-control study. *Vaccine.* 2010;28(47):7460–7. [PubMed: 20875486]
82. Puig-Barbera J, Diez-Domingo J, Arnedo-Pena A, Ruiz-Garcia M, Perez-Vilar S, Mico-Esparza JL, et al. Effectiveness of the 2010–2011 seasonal influenza vaccine in preventing confirmed influenza hospitalizations in adults: a case-case comparison, case-control study. *Vaccine.* 2012;30(39):5714–20. [PubMed: 22819720]

83. Puig-Barbera J, Natividad-Sancho A, Launay O, Burtseva E, Ciblak MA, Tormos A, et al. 2012–2013 Seasonal influenza vaccine effectiveness against influenza hospitalizations: results from the global influenza hospital surveillance network. *PLoS One*. 2014;9(6):e100497. [PubMed: 24945510]
84. Rony M, Puig-Barbera J, Launay O, Duval X, Castilla J, Guevara M, et al. 2011–12 seasonal influenza vaccines effectiveness against confirmed A(H3N2) influenza hospitalisation: pooled analysis from a European network of hospitals. A pilot study. *PLoS One*. 2013;8(4):e59681. [PubMed: 23565159]
85. Savulescu C, Valenciano M, de Mateo S, Larrauri A. Estimating the influenza vaccine effectiveness in elderly on a yearly basis using the Spanish influenza surveillance network—pilot case-control studies using different control groups, 2008–2009 season, Spain. *Vaccine*. 2010;28(16):2903–7. [PubMed: 20153351]
86. Savulescu C, Jimenez-Jorge S, de Mateo S, Pozo F, Casas I, Brena PP, et al. Using surveillance data to estimate pandemic vaccine effectiveness against laboratory confirmed influenza A(H1N1)2009 infection: two case-control studies, Spain, season 2009–2010. *BMC Public Health*. 2011;11:899. [PubMed: 22129083]
87. Savulescu C, Jimenez-Jorge S, Delgado-Sanz C, de Mateo S, Pozo F, Casas I, et al. Higher vaccine effectiveness in seasons with predominant circulation of seasonal influenza A(H1N1) than in A(H3N2) seasons: test-negative case-control studies using surveillance data, Spain, 2003–2011. *Vaccine*. 2014;32(35):4404–11. [PubMed: 24968153]
88. Skowronski DM, Masaro C, Kwindt TL, Mak A, Petric M, Li Y, et al. Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005–2006 season of dual A and B vaccine mismatch in Canada. *Vaccine*. 2007;25(15):2842–51. [PubMed: 17081662]
89. Skowronski DM, De Serres G, Dickinson J, Petric M, Mak A, Fonseca K, et al. Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006–2007. *J Infect Dis*. 2009;199(2):168–79. [PubMed: 19086914]
90. Skowronski DM, De Serres G, Crowcroft NS, Janjua NZ, Boulianne N, Hottes TS, et al. Association between the 2008–09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada. *PLoS Med*. 2010;7(4):e1000258. [PubMed: 20386731]
91. Skowronski DM, Janjua NZ, De Serres G, Hottes TS, Dickinson JA, Crowcroft N, et al. Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009. *BMJ*. 2011;342:c7297. [PubMed: 21292718]
92. Skowronski DM, Janjua NZ, De Serres G, Winter A-L, Dickinson JA, Gardy JL, et al. A sentinel platform to evaluate influenza vaccine effectiveness and new variant circulation, Canada 2010–2011 season. *Clin Infect Dis*. 2012;55(3):332–42. [PubMed: 22539661]
93. Skowronski DM, Janjua NZ, Sabaiduc S, De Serres G, Winter AL, Gubbay JB, et al. Influenza A/subtype and B/lineage effectiveness estimates for the 2011–2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine. *J Infect Dis*. 2014;210(1):126–37. [PubMed: 24446529]
94. Song JY, Cheong HJ, Heo JY, Noh JY, Choi WS, Park DW, et al. Effectiveness of the pandemic influenza A/H1N1 2009 monovalent vaccine in Korea. *Vaccine*. 2011;29(7):1395–8. [PubMed: 21199701]
95. Staat MA, Griffin MR, Donauer S, Edwards KM, Szilagyi PG, Weinberg GA, et al. Vaccine effectiveness for laboratory-confirmed influenza in children 6–59 months of age, 2005–2007. *Vaccine*. 2011;29(48):9005–11. [PubMed: 21945256]
96. Sullivan SG, Komadina N, Grant K, Jelley L, Papadakis G, Kelly H. Influenza vaccine effectiveness during the 2012 influenza season in Victoria, Australia: influences of waning immunity and vaccine match. *J Med Virol*. 2014;86(6):1017–25. [PubMed: 24395730]
97. Sullivan SG, Chilver MB, Higgins G, Cheng AC, Stocks NP. Influenza vaccine effectiveness in Australia: results from the Australian Sentinel Practices Research Network. *Med J Aust*. 2014;201(2):109–11. [PubMed: 25045991]

98. Sundaram ME, McClure DL, VanWormer JJ, Friedrich TC, Meece JK, Belongia EA. Influenza vaccination is not associated with detection of noninfluenza respiratory viruses in seasonal studies of influenza vaccine effectiveness. *Clin Infect Dis*. 2013;57(6):789–93. [PubMed: 23748138]
99. Suzuki M, Yoshimine H, Harada Y, Tsuchiya N, Shimada I, Ariyoshi K, et al. Estimating the influenza vaccine effectiveness against medically attended influenza in clinical settings: a hospital-based case–control study with a rapid diagnostic test in Japan. *PLoS One*. 2013;8(1):e52103. [PubMed: 23326324]
100. Suzuki M, Minh le N, Yoshimine H, Inoue K, Yoshida LM, Morimoto K, et al. Vaccine effectiveness against medically attended laboratory-confirmed influenza in Japan, 2011–2012 Season. *PLoS One*. 2014;9(2):e88813. [PubMed: 24551167]
101. Talbot HK, Griffin MR, Chen Q, Zhu Y, Williams JV, Edwards KM. Effectiveness of seasonal vaccine in preventing confirmed influenza-associated hospitalizations in community dwelling older adults. *J Infect Dis*. 2011;203(4):500–8. [PubMed: 21220776]
102. Talbot HK, Zhu Y, Chen Q, Williams JV, Thompson MG, Griffin MR. Effectiveness of influenza vaccine for preventing laboratory-confirmed influenza hospitalizations in adults, 2011–2012 influenza season. *Clin Infect Dis*. 2013;56(12):1774–7. [PubMed: 23449269]
103. Thompson MG, Li DK, Shifflett P, Sokolow LZ, Ferber JR, Kurosky S, et al. Effectiveness of seasonal trivalent influenza vaccine for preventing influenza virus illness among pregnant women: a population-based case–control study during the 2010–2011 and 2011–2012 influenza seasons. *Clin Infect Dis*. 2014;58(4):449–57. [PubMed: 24280090]
104. Treanor JJ, Talbot HK, Ohmit SE, Coleman LA, Thompson MG, Cheng PY, et al. Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains. *Clin Infect Dis*. 2012;55(7):951–9. [PubMed: 22843783]
105. Turner N, Pierse N, Bissielo A, Huang QS, Baker MG, Widdowson MA, et al. The effectiveness of seasonal trivalent inactivated influenza vaccine in preventing laboratory confirmed influenza hospitalisations in Auckland, New Zealand in 2012. *Vaccine*. 2014;32(29):3687–93. [PubMed: 24768730]
106. Uphoff H, An der Heiden M, Schweiger B, Campe H, Beier D, Helmeke C, et al. Effectiveness of the AS03-adjuvanted vaccine against pandemic influenza virus A/(H1N1) 2009--a comparison of two methods; Germany, 2009/10. *PLoS One*. 2011;6(7):e19932. [PubMed: 21789163]
107. Valenciano M, Kissling E, Cohen JM, Oroszi B, Barret AS, Rizzo C, et al. Estimates of pandemic influenza vaccine effectiveness in Europe, 2009–2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case–control study. *PLoS Med*. 2011;8(1):e1000388. [PubMed: 21379316]
108. Van Buynder PG, Dhaliwal JK, Van Buynder JL, Couturier C, Minville-Leblanc M, Garceau R, et al. Protective effect of single-dose adjuvanted pandemic influenza vaccine in children. *Influenza Other Respir Viruses*. 2010;4(4):171–8. [PubMed: 20629771]
109. Van Buynder PG, Konrad S, Van Buynder JL, Brodtkin E, Krajden M, Ramler G, et al. The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. *Vaccine*. 2013;31(51):6122–8. [PubMed: 23933368]
110. Yang P, Thompson MG, Ma C, Shi W, Wu S, Zhang D, et al. Influenza vaccine effectiveness against medically-attended influenza illness during the 2012–2013 season in Beijing, China. *Vaccine*. 2014;32(41):5285–9. [PubMed: 25092635]
111. Joshi AY, Iyer VN, St Sauver JL, Jacobson RM, Boyce TG. Effectiveness of inactivated influenza vaccine in children less than 5 years of age over multiple influenza seasons: a case–control study. *Vaccine*. 2009;27(33):4457–61. [PubMed: 19490957]
112. Benowitz I, Esposito DB, Gracey KD, Shapiro ED, Vazquez M. Influenza vaccine given to pregnant women reduces hospitalization due to influenza in their infants. *Clin Infect Dis*. 2010;51(12):1355–61. [PubMed: 21058908]
113. Cochran LW, Black S, Klein NP, Dekker CL, Lewis E, Reingold AL. Vaccine effectiveness against laboratory-confirmed influenza in infants: A matched case control study. *Hum Vaccin*. 2010;6(9):729–35.



114. Menniti-Ippolito F, Da Cas R, Sagliocca L, Traversa G, Ferrazin F, Santuccio C, et al. Effectiveness and safety of the A-H1N1 vaccine in children: a hospital-based case-control study. *BMJ Open*. 2011;1(2):e000167.
115. Ikematsu H, Takeuchi Y, Rosenlund M, Kawai N, Shimamura R, Hirata M, et al. The post-infection outcomes of influenza and acute respiratory infection in patients above 50 years of age in Japan: an observational study. *Influenza Other Respir Viruses*. 2012;6(3):211–7. [PubMed: 21985038]
116. Bragstad K, Emborg H, Fischer TK, Voldstedlund M, Gubbels S, Andersen B, et al. Low vaccine effectiveness against influenza A(H3N2) virus among elderly people in Denmark in 2012/13--a rapid epidemiological and virological assessment. *Euro Surveill*. 2013;18(6):pii=20397.
117. Cheng AC, Brown S, Waterer G, Holmes M, Senenayake S, Friedman ND, et al. Influenza epidemiology, vaccine coverage and vaccine effectiveness in sentinel Australian hospitals in 2012: the Influenza Complications Alert Network (FluCAN). *Commun Dis Intell Q Rep*. 2013;37(3):E246–52. [PubMed: 24890961]
118. Choi WS, Noh JY, Seo YB, Baek JH, Lee J, Song JY, et al. Case-control study of the effectiveness of the 2010–2011 seasonal influenza vaccine for prevention of laboratory-confirmed influenza virus infection in the Korean adult population. *Clin Vaccine Immunol*. 2013;20(6):877–81. [PubMed: 23576674]
119. Kavanagh K, Robertson C, McMenamin J. Estimates of influenza vaccine effectiveness in primary care in Scotland vary with clinical or laboratory endpoint and method--experience across the 2010/11 season. *Vaccine*. 2013;31(41):4556–63. [PubMed: 23933371]
120. Kelly HA, Sullivan SG, Grant KA, Fielding JE. Moderate influenza vaccine effectiveness with variable effectiveness by match between circulating and vaccine strains in Australian adults aged 20–64 years, 2007–2011. *Influenza Other Respir Viruses*. 2013;7(5):729–37. [PubMed: 23078073]
121. MacIntosh VH, Tastad KJ, Eick-Cost AA. Mid-season influenza vaccine effectiveness 2011–2012: a Department of Defense Global, Laboratory-based, Influenza Surveillance System case-control study estimate. *Vaccine*. 2013;31(13):1651–5. [PubMed: 23395733]
122. Wijnans L, Dieleman J, Voordouw B, Sturkenboom M. Effectiveness of MF59 adjuvanted influenza A(H1N1)pdm09 vaccine in risk groups in the Netherlands. *PLoS One*. 2013;8(4):e63156. [PubMed: 23646191]
123. Cheng AC, Dwyer DE, Holmes M, Irving LB, Brown SG, Waterer GW, et al. Influenza epidemiology, vaccine coverage and vaccine effectiveness in sentinel Australian hospitals in 2013: the Influenza Complications Alert Network. *Commun Dis Intell Q Rep*. 2014;38(2):E143–9. [PubMed: 25222208]
124. Cost AA, Hiser MJ, Hu Z, Cooper MJ, Hawksworth AW, Radin JM, et al. Brief report: mid-season influenza vaccine effectiveness estimates for the 2013–2014 influenza season. *MSMR*. 2014;21(6):15–7.
125. Kulkarni PS, Agarkhedkar S, Lalwani S, Bavdekar AR, Jog S, Raut SK, et al. Effectiveness of an Indian-made attenuated influenza A(H1N1)pdm 2009 vaccine: a case control study. *Hum Vaccin Immunother*. 2014;10(3):566–71. [PubMed: 24406308]
126. Levy A, Sullivan SG, Tempone SS, Wong KL, Regan AK, Dowse GK, et al. Influenza vaccine effectiveness estimates for Western Australia during a period of vaccine and virus strain stability, 2010 to 2012. *Vaccine*. 2014;32(47):6312–8. [PubMed: 25223268]
127. Martinez-Baz I, Guevara M, Elia F, Ezpeleta C, Fernandez Alonso M, Castilla J. Influence of distinct criteria for selecting patients for swabbing on estimation of the effectiveness of the influenza vaccine. *Gac Sanit*. 2014;28(3):225–9. [PubMed: 24315408]
128. McNeil S, Shinde V, Andrew M, Hachette T, Leblanc J, Ambrose A, et al. Interim estimates of 2013/14 influenza clinical severity and vaccine effectiveness in the prevention of laboratory-confirmed influenza-related hospitalisation, Canada, February 2014. *Euro Surveill*. 2014;19(9):pii=20729.
129. Puig-Barbera J, Garcia-de-Lomas J, Diez-Domingo J, Arnedo-Pena A, Ruiz-Garcia M, Limon-Ramirez R, et al. Influenza vaccine effectiveness in preventing influenza A(H3N2)-related hospitalizations in adults targeted for vaccination by type of vaccine: a hospital-based test-



- negative study, 2011–2012 A(H3N2) predominant influenza season, Valencia, Spain. *PLoS One*. 2014;9(11):e112294. [PubMed: 25392931]
130. Skowronski DM, Janjua NZ, De Serres G, Sabaiduc S, Eshaghi A, Dickinson JA, et al. Low 2012–13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. *PLoS One*. 2014;9(3):e92153. [PubMed: 24667168]
  131. Turner N, Pierse N, Bissielo A, Huang Q, Radke S, Baker M, et al. Effectiveness of seasonal trivalent inactivated influenza vaccine in preventing influenza hospitalisations and primary care visits in Auckland, New Zealand, in 2013. *Euro Surveill*. 2014;19(34):pii=20884.
  132. Belongia EA, Sundaram ME, McClure DL, Meece JK, Ferdinands J, VanWormer JJ. Waning vaccine protection against influenza A (H3N2) illness in children and older adults during a single season. *Vaccine*. 2015;33(1):246–51. [PubMed: 24962752]
  133. Blyth CC, Cheng AC, Finucane C, Jacoby P, Effler PV, Smith DW, et al. The effectiveness of influenza vaccination in preventing hospitalisation in children in Western Australia. *Vaccine*. 2015;33(51):7239–44. [PubMed: 26549359]
  134. Carville KS, Grant KA, Sullivan SG, Fielding JE, Lane CR, Franklin L, et al. Understanding influenza vaccine protection in the community: an assessment of the 2013 influenza season in Victoria, Australia. *Vaccine*. 2015;33(2):341–5. [PubMed: 25448093]
  135. Chen Q, Griffin MR, Nian H, Zhu Y, Williams JV, Edwards KM, et al. Influenza vaccine prevents medically attended influenza-associated acute respiratory illness in adults aged  $\geq 50$  years. *J Infect Dis*. 2015;211(7):1045–50. [PubMed: 25336724]
  136. Cheng AC, Kotsimbos T, Kelly PM. Influenza vaccine effectiveness against hospitalisation with influenza in adults in Australia in 2014. *Vaccine*. 2015;33(51):7352–6. [PubMed: 26529066]
  137. Choi WS, Noh JY, Baek JH, Seo YB, Lee J, Song JY, et al. Suboptimal effectiveness of the 2011–2012 seasonal influenza vaccine in adult Korean populations. *PLoS One*. 2015;10(3):e0098716. [PubMed: 25815717]
  138. El Omeiri N, Azziz-Baumgartner E, Clara W, Guzman-Saborio G, Elas M, Mejia H, et al. Pilot to evaluate the feasibility of measuring seasonal influenza vaccine effectiveness using surveillance platforms in Central-America, 2012. *BMC Public Health*. 2015;15:673. [PubMed: 26184659]
  139. Gilca R, Skowronski DM, Douville-Fradet M, Amini R, Boulianne N, Rouleau I, et al. Mid-Season Estimates of Influenza Vaccine Effectiveness against Influenza A(H3N2) Hospitalization in the Elderly in Quebec, Canada, January 2015. *PLoS One*. 2015;10(7):e0132195. [PubMed: 26200655]
  140. Grijalva CG, Zhu Y, Williams DJ, Self WH, Ampofo K, Pavia AT, et al. Association Between Hospitalization With Community-Acquired Laboratory-Confirmed Influenza Pneumonia and Prior Receipt of Influenza Vaccination. *JAMA*. 2015;314(14):1488–97. [PubMed: 26436611]
  141. Helmeke C, Grafe L, Irmscher HM, Gottschalk C, Karagiannis I, Oppermann H. Effectiveness of the 2012/13 trivalent live and inactivated influenza vaccines in children and adolescents in Saxony-Anhalt, Germany: a test-negative case–control study. *PLoS One*. 2015;10(4):e0122910. [PubMed: 25885063]
  142. Jimenez-Jorge S, de Mateo S, Delgado-Sanz C, Pozo F, Casas I, Garcia-Cenoz M, et al. Estimating influenza vaccine effectiveness in Spain using sentinel surveillance data. *Euro Surveill*. 2015;20(28):pii=21187.
  143. Jimenez-Jorge S, Pozo F, Larrauri A. Interim influenza vaccine effectiveness: A good proxy for final estimates in Spain in the seasons 2010–2014. *Vaccine*. 2015;33(29):3276–80. [PubMed: 25869892]
  144. Kurecic Filipovic S, Gjenero-Margan I, Kissling E, Kaic B, Cvitkovic A. Influenza vaccine effectiveness estimates in Croatia in 2010–2011: a season with predominant circulation of A(H1N1)pdm09 influenza virus. *Epidemiol Infect*. 2015;143(12):2596–603. [PubMed: 25567212]
  145. Levy JW, Simasathien S, Watanaveeradej V, Bhoomiboonchoo P, Fernandez S, Jarman RG, et al. Influenza vaccine effectiveness in the tropics: moderate protection in a case test-negative analysis of a hospital-based surveillance population in Bangkok between August 2009 and January 2013. *PLoS One*. 2015;10(8):e0134318. [PubMed: 26267430]

146. Lytras T, Kossovakis A, Melidou A, Exindari M, Gioula G, Pogka V, et al. Influenza vaccine effectiveness against laboratory confirmed influenza in Greece during the 2013–2014 season: a test-negative study. *Vaccine*. 2015;33(2):367–73. [PubMed: 25448097]
147. Martinez-Baz I, Navascues A, Pozo F, Chamorro J, Albeniz E, Casado I, et al. Influenza vaccine effectiveness in preventing inpatient and outpatient cases in a season dominated by vaccine-matched influenza B virus. *Hum Vaccin Immunother*. 2015;11(7):1626–33. [PubMed: 25996366]
148. McAnerney JM, Treurnicht F, Walaza S, Cohen AL, Tempia S, Mtshali S, et al. Evaluation of influenza vaccine effectiveness and description of circulating strains in outpatient settings in South Africa, 2014. *Influenza Other Respir Viruses*. 2015;9(4):209–15. [PubMed: 25865249]
149. McAnerney JM, Walaza S, Cohen AL, Tempia S, Buys A, Venter M, et al. Effectiveness and knowledge, attitudes and practices of seasonal influenza vaccine in primary healthcare settings in South Africa, 2010–2013. *Influenza Other Respir Viruses*. 2015;9(3):143–50. [PubMed: 25677874]
150. McLean HQ, Thompson MG, Sundaram ME, Kieke BA, Gaglani M, Murthy K, et al. Influenza vaccine effectiveness in the United States during 2012–2013: variable protection by age and virus type. *J Infect Dis*. 2015;211(10):1529–40. [PubMed: 25406334]
151. McNeil SA, Andrew MK, Ye L, Haguinet F, Hatchette TF, ElSherif M, et al. Interim estimates of 2014/15 influenza vaccine effectiveness in preventing laboratory-confirmed influenza-related hospitalisation from the Serious Outcomes Surveillance Network of the Canadian Immunization Research Network, January 2015. *Euro Surveill*. 2015;20(5):pii=21024.
152. Ortqvist A, Bennet R, Hamrin J, Rinder MR, Lindblad H, Ohd JN, et al. Long term effectiveness of adjuvanted influenza A(H1N1)pdm09 vaccine in children. *Vaccine*. 2015;33(22):2558–61. [PubMed: 25869891]
153. Pebody R, Warburton F, Andrews N, Ellis J, von Wissmann B, Robertson C, et al. Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 end of season results. *Euro Surveill*. 2015;20(36):pii=30013.
154. Rondy M, Launay O, Puig-Barbera J, Gefenaite G, Castilla J, de Gaetano Donati K, et al. 2012/13 influenza vaccine effectiveness against hospitalised influenza A(H1N1)pdm09, A(H3N2) and B: estimates from a European network of hospitals. *Euro Surveill*. 2015;20(2):pii=21011.
155. Savage RD, Winter AL, Rosella LC, Olsha R, Gubbay JB, Skowronski DM, et al. Strengths and limitations of assessing influenza vaccine effectiveness using routinely collected, passive surveillance data in Ontario, Canada, 2007 to 2012: balancing efficiency versus quality. *Euro Surveill*. 2015;20(16):pii=21100.
156. Shinjoh M, Sugaya N, Yamaguchi Y, Tomidokoro Y, Sekiguchi S, Mitamura K, et al. Effectiveness of Trivalent Inactivated Influenza Vaccine in Children Estimated by a Test-Negative Case-control Design Study Based on Influenza Rapid Diagnostic Test Results. *PLoS One*. 2015;10(8):e0136539. [PubMed: 26317334]
157. Simpson CR, Lone NI, Kavanagh K, Ritchie LD, Robertson C, Sheikh A, et al. Trivalent inactivated seasonal influenza vaccine effectiveness for the prevention of laboratory-confirmed influenza in a Scottish population 2000 to 2009. *Euro Surveill*. 2015;20(8):pii=21043.
158. Su WJ, Chan TC, Chuang PH, Liu YL, Lee PI, Liu MT, et al. Estimating influenza vaccine effectiveness using routine surveillance data among children aged 6–59 months for five consecutive influenza seasons. *Int J Infect Dis*. 2015;30:115–21. [PubMed: 25462180]
159. Talbot HK, Nian H, Zhu Y, Chen Q, Williams JV, Griffin MR. Clinical effectiveness of split-virion versus subunit trivalent influenza vaccines in older adults. *Clin Infect Dis*. 2015;60(8):1170–5. [PubMed: 25697739]
160. Torner N, Martinez A, Basile L, Marcos MA, Anton A, Mar Mosquera M, et al. Influenza vaccine effectiveness assessment through sentinel virological data in three post-pandemic seasons. *Hum Vaccin Immunother*. 2015;11(1):225–30. [PubMed: 25483540]
161. Valenciano M, Kissling E, Reuss A, Jimenez-Jorge S, Horvath JK, Donnell JM, et al. The European I-MOVE Multicentre 2013–2014 Case-control Study. Homogeneous moderate influenza vaccine effectiveness against A(H1N1)pdm09 and heterogenous results by country against A(H3N2). *Vaccine*. 2015;33(24):2813–22. [PubMed: 25936723]

162. Bissielo A, Pierse N, Huang QS, Thompson MG, Kelly H, Mishin VP, et al. Effectiveness of seasonal influenza vaccine in preventing influenza primary care visits and hospitalisation in Auckland, New Zealand in 2015: interim estimates. *Euro Surveill.* 2016;21(1):pii=30101.
163. Blyth CC, Jacoby P, Effler PV, Kelly H, Smith DW, Borland ML, et al. Influenza Vaccine Effectiveness and Uptake in Children at Risk of Severe Disease. *Pediatr Infect Dis J.* 2016;35(3):309–15. [PubMed: 26646548]
164. Blyth CC, Macartney KK, Hewagama S, Senenayake S, Friedman ND, Simpson G, et al. Influenza epidemiology, vaccine coverage and vaccine effectiveness in children admitted to sentinel Australian hospitals in 2014: the Influenza Complications Alert Network (FluCAN). *Euro Surveill.* 2016;21(30):pii=30301.
165. Caspard H, Coelingh KL, Mallory RM, Ambrose CS. Association of vaccine handling conditions with effectiveness of live attenuated influenza vaccine against H1N1pdm09 viruses in the United States. *Vaccine.* 2016;34(42):5066–72. [PubMed: 27613072]
166. Caspard H, Gaglani M, Clipper L, Belongia EA, McLean HQ, Griffin MR, et al. Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children 2–17 years of age in 2013–2014 in the United States. *Vaccine.* 2016;34(1):77–82. [PubMed: 26589519]
167. Castilla J, Navascues A, Fernandez-Alonso M, Reina G, Albeniz E, Pozo F, et al. Effects of previous episodes of influenza and vaccination in preventing laboratory-confirmed influenza in Navarre, Spain, 2013/14 season. *Euro Surveill.* 2016;20(22):pii=30243.
168. Castilla J, Navascues A, Fernandez-Alonso M, Reina G, Pozo F, Casado I, et al. Effectiveness of subunit influenza vaccination in the 2014–2015 season and residual effect of split vaccination in previous seasons. *Vaccine.* 2016;34(11):1350–7. [PubMed: 26854911]
169. Chiu SS, Feng S, Chan KH, Lo JY, Chan EL, So LY, et al. Hospital-based vaccine effectiveness against influenza B lineages, Hong Kong, 2009–14. *Vaccine.* 2016;34(19):2164–9. [PubMed: 27013437]
170. Emborg HD, Krause TG, Nielsen L, Thomsen MK, Christiansen CB, Skov MN, et al. Influenza vaccine effectiveness in adults 65 years and older, Denmark, 2015/16 - a rapid epidemiological and virological assessment. *Euro Surveill.* 2016;21(14):pii=30189.
171. Fielding JE, Levy A, Chilver MB, Deng YM, Regan AK, Grant KA, et al. Effectiveness of seasonal influenza vaccine in Australia, 2015: An epidemiological, antigenic and phylogenetic assessment. *Vaccine.* 2016;34(41):4905–12. [PubMed: 27577556]
172. Flannery B, Zimmerman RK, Gubareva LV, Garten RJ, Chung JR, Nowalk MP, et al. Enhanced Genetic Characterization of Influenza A(H3N2) Viruses and Vaccine Effectiveness by Genetic Group, 2014–2015. *J Infect Dis.* 2016;214(7):1010–9. [PubMed: 27190176]
173. Gaglani M, Pruszynski J, Murthy K, Clipper L, Robertson A, Reis M, et al. Influenza Vaccine Effectiveness Against 2009 Pandemic Influenza A(H1N1) Virus Differed by Vaccine Type During 2013–2014 in the United States. *J Infect Dis.* 2016;213(10):1546–56. [PubMed: 26743842]
174. Gherasim A, Pozo F, de Mateo S, Gamarra IA, Garcia-Cenoz M, Vega T, et al. Waning protection of influenza vaccine against mild laboratory confirmed influenza A(H3N2) and B in Spain, season 2014–15. *Vaccine.* 2016;34(20):2371–7. [PubMed: 27020713]
175. Katz MA, Lebo E, Emukule GO, Otieno N, Caselton DL, Bigogo G, et al. Uptake and Effectiveness of a Trivalent Inactivated Influenza Vaccine in Children in Urban and Rural Kenya, 2010 to 2012. *Pediatr Infect Dis J.* 2016;35(3):322–9. [PubMed: 26658627]
176. Kelly HA, Lane C, Cheng AC. Influenza vaccine effectiveness in general practice and in hospital patients in Victoria, 2011–2013. *Med J Aust.* 2016;204(2):76.e1–4. [PubMed: 26821109]
177. Kissling E, Nunes B, Robertson C, Valenciano M, Reuss A, Larrauri A, et al. I-MOVE multicentre case–control study 2010/11 to 2014/15: Is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination? *Euro Surveill.* 2016;21(16):pii=30201.
178. Kittikraisak W, Suntarattiwong P, Ditsungnoen D, Klungthong C, Fernandez S, Yoon IK, et al. Effectiveness of the 2013 and 2014 Southern Hemisphere Influenza Vaccines Against Laboratory-confirmed Influenza in Young Children Using a Test-negative Design, Bangkok, Thailand. *Pediatr Infect Dis J.* 2016;35(10):e318–25. [PubMed: 27307102]

179. Lane CR, Carville KS, Pierse N, Kelly HA. Seasonal influenza vaccine effectiveness estimates: Development of a parsimonious case test negative model using a causal approach. *Vaccine*. 2016;34(8):1070–6. [PubMed: 26795366]
180. Lytras T, Kossyvakis A, Melidou A, Andreopoulou A, Exindari M, Gioula G, et al. Influenza vaccine effectiveness in preventing hospitalizations with laboratory-confirmed influenza in Greece during the 2014–2015 season: A test-negative study. *J Med Virol*. 2016;88(11):1896–904. [PubMed: 27088266]
181. Pebody R, Warburton F, Ellis J, Andrews N, Potts A, Cottrell S, et al. Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results. *Euro Surveill*. 2016;21(38):pii=30348.
182. Petrie JG, Ohmit SE, Cheng CK, Martin ET, Malosh RE, Luring AS, et al. Influenza Vaccine Effectiveness Against Antigenically Drifted Influenza Higher Than Expected in Hospitalized Adults: 2014–2015. *Clin Infect Dis*. 2016;63(8):1017–25. [PubMed: 27369320]
183. Pierse N, Kelly H, Thompson MG, Bissielo A, Radke S, Huang QS, et al. Influenza vaccine effectiveness for hospital and community patients using control groups with and without non-influenza respiratory viruses detected, Auckland, New Zealand 2014. *Vaccine*. 2016;34(4):503–9. [PubMed: 26685091]
184. Qin Y, Zhang Y, Wu P, Feng S, Zheng J, Yang P, et al. Influenza vaccine effectiveness in preventing hospitalization among Beijing residents in China, 2013–15. *Vaccine*. 2016;34(20):2329–33. [PubMed: 27026147]
185. Redlberger-Fritz M, Kundi M, Popow-Kraupp T. Detailed Report on 2014/15 Influenza Virus Characteristics, and Estimates on Influenza Virus Vaccine Effectiveness from Austria's Sentinel Physician Surveillance Network. *PLoS One*. 2016;11(3):e0149916. [PubMed: 26975056]
186. Rizzo C, Bella A, Alfonsi V, Puzelli S, Palmieri AP, Chironna M, et al. Influenza vaccine effectiveness in Italy: Age, subtype-specific and vaccine type estimates 2014/15 season. *Vaccine*. 2016;34(27):3102–8. [PubMed: 27154392]
187. Rondy M, Castilla J, Launay O, Costanzo S, Ezpeleta C, Galtier F, et al. Moderate influenza vaccine effectiveness against hospitalisation with A(H3N2) and A(H1N1) influenza in 2013–14: Results from the InNHOVE network. *Hum Vaccin Immunother*. 2016;12(5):1217–24. [PubMed: 27065000]
188. Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Winter AL, Dickinson JA, et al. A Perfect Storm: Impact of Genomic Variation and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014–2015 Season. *Clin Infect Dis*. 2016;63(1):21–32. [PubMed: 27025838]
189. Sugaya N, Shinjoh M, Kawakami C, Yamaguchi Y, Yoshida M, Baba H, et al. Trivalent inactivated influenza vaccine effective against influenza A(H3N2) variant viruses in children during the 2014/15 season, Japan. *Euro Surveill*. 2016;21(42):pii=30377.
190. Talbot HK, Nian H, Chen Q, Zhu Y, Edwards KM, Griffin MR. Evaluating the case-positive, control test-negative study design for influenza vaccine effectiveness for the frailty bias. *Vaccine*. 2016;34(15):1806–9. [PubMed: 26930368]
191. Thompson MG, Clippard J, Petrie JG, Jackson ML, McLean HQ, Gaglani M, et al. Influenza Vaccine Effectiveness for Fully and Partially Vaccinated Children 6 Months to 8 Years Old During 2011–2012 and 2012–2013: The Importance of Two Priming Doses. *Pediatr Infect Dis J*. 2016;35(3):299–308. [PubMed: 26658375]
192. Valenciano M, Kissling E, Reuss A, Rizzo C, Gherasim A, Horvath JK, et al. Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-control Study, Europe 2014/15. *Euro Surveill*. 2016;21(7):pii=30139.
193. Vanhems P, Baghdadi Y, Roche S, Benet T, Regis C, Lina B, et al. Influenza vaccine effectiveness among healthcare workers in comparison to hospitalized patients: A 2004–2009 case-test, negative-control, prospective study. *Hum Vaccin Immunother*. 2016;12(2):485–90. [PubMed: 26327520]
194. Wang Y, Zhang T, Chen L, Greene C, Ding Y, Cheng Y, et al. Seasonal influenza vaccine effectiveness against medically attended influenza illness among children aged 6–59 months,

- October 2011–September 2012: A matched test-negative case–control study in Suzhou, China. *Vaccine*. 2016;34(21):2460–5. [PubMed: 27016650]
195. Zimmerman RK, Nowalk MP, Chung J, Jackson ML, Jackson LA, Petrie JG, et al. 2014–2015 Influenza Vaccine Effectiveness in the United States by Vaccine Type. *Clin Infect Dis*. 2016;63(12):1564–73. [PubMed: 27702768]
  196. Andrew MK, Shinde V, Ye L, Hachette T, Haguinet F, Dos Santos G, et al. The Importance of Frailty in the Assessment of Influenza Vaccine Effectiveness Against Influenza-Related Hospitalization in Elderly People. *J Infect Dis*. 2017;216(4):405–14. [PubMed: 28931244]
  197. Cheng AC, Macartney KK, Waterer GW, Kotsimbos T, Kelly PM, Blyth CC. Repeated Vaccination Does Not Appear to Impact Upon Influenza Vaccine Effectiveness Against Hospitalization With Confirmed Influenza. *Clin Infect Dis*. 2017;64(11):1564–72. [PubMed: 28329167]
  198. Cowling BJ, Kwan MY, Wong JS, Feng S, Leung CW, Chan EL, et al. Interim estimates of the effectiveness of influenza vaccination against influenza-associated hospitalization in children in Hong Kong, 2015–16. *Influenza Other Respir Viruses*. 2017;11(1):61–5. [PubMed: 27313064]
  199. Darvishian M, Dijkstra F, van Doorn E, Bijlsma MJ, Donker GA, de Lange MM, et al. Influenza Vaccine Effectiveness in the Netherlands from 2003/2004 through 2013/2014: The Importance of Circulating Influenza Virus Types and Subtypes. *PLoS One*. 2017;12(1):e0169528. [PubMed: 28068386]
  200. El Omeiri N, Azziz-Baumgartner E, Thompson MG, Clara W, Cerpa M, Palekar R, et al. Seasonal influenza vaccine effectiveness against laboratory-confirmed influenza hospitalizations - Latin America, 2013. *Vaccine*. 2017;36(24):3555–66. [PubMed: 28648543]
  201. Feng S, Fowlkes AL, Steffens A, Finelli L, Cowling BJ. Assessment of Virus Interference in a Test-negative Study of Influenza Vaccine Effectiveness. *Epidemiology*. 2017;28(4):514–24. [PubMed: 28362642]
  202. Ferdinands JM, Fry AM, Reynolds S, Petrie J, Flannery B, Jackson ML, et al. Intraseason waning of influenza vaccine protection: Evidence from the US Influenza Vaccine Effectiveness Network, 2011–12 through 2014–15. *Clin Infect Dis*. 2017;64(5):544–50. [PubMed: 28039340]
  203. Gherasim A, Martinez-Baz I, Castilla J, Pozo F, Larrauri A. Effect of previous and current vaccination against influenza A(H1N1)pdm09, A(H3N2), and B during the post-pandemic period 2010–2016 in Spain. *PLoS One*. 2017;12(6):e0179160. [PubMed: 28614376]
  204. Hekimoglu CH, Emek M, Avci E, Topal S, Demiroz M, Ergor G. Seasonal Influenza Vaccine Effectiveness in Preventing Laboratory Confirmed Influenza in 2014–2015 season in Turkey: A Test-Negative Case Control Study. *Balkan Med J*. 2017;35(1):77–83. [PubMed: 28903887]
  205. Jackson ML, Chung JR, Jackson LA, Phillips CH, Benoit J, Monto AS, et al. Influenza Vaccine Effectiveness in the United States during the 2015–2016 Season. *N Engl J Med*. 2017;377(6):534–43. [PubMed: 28792867]
  206. Kuliese M, Jancoriene L, Grimalauskaite R, Zablockiene B, Damuleviciene G, Velyvyte D, et al. Seasonal influenza vaccine effectiveness against laboratory-confirmed influenza in 2015–2016: a hospital-based test-negative case–control study in Lithuania. *BMJ Open*. 2017;7(10):e017835.
  207. Ma C, Pan Y, Zhang L, Zhang Y, Wu S, Sun Y, et al. Influenza vaccine effectiveness against medically attended influenza illness in Beijing, China, 2014/15 season. *Hum Vaccin Immunother*. 2017;13(10):2379–84. [PubMed: 28846480]
  208. Martinez-Baz I, Casado I, Navascues A, Diaz-Gonzalez J, Aguinaga A, Barrado L, et al. Effect of Repeated Vaccination With the Same Vaccine Component Against 2009 Pandemic Influenza A(H1N1) Virus. *J Infect Dis*. 2017;215(6):847–55. [PubMed: 28453845]
  209. McAnerney JM, Walaza S, Tempia S, Blumberg L, Treurnicht FK, Madhi SA, et al. Estimating vaccine effectiveness in preventing laboratory-confirmed influenza in outpatient settings in South Africa, 2015. *Influenza Other Respir Viruses*. 2017;11(2):177–81. [PubMed: 27865064]
  210. McLean HQ, Caspard H, Griffin MR, Poehling KA, Gaglani M, Belongia EA, et al. Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children during the 2014–2015 season. *Vaccine*. 2017;35(20):2685–93. [PubMed: 28408121]



211. Noh JY, Lim S, Song JY, Choi WS, Jeong HW, Heo JY, et al. Interim estimates of the effectiveness of the influenza vaccine against A(H3N2) influenza in adults in South Korea, 2016–2017 season. *PLoS One*. 2017;12(5):e0178010. [PubMed: 28542417]
212. Paradowska-Stankiewicz I, Korczynska MR, Cieslak K, Kowalczyk D, Szymanski K, Brydak LB. Vaccine Effectiveness against Influenza in 2015/16 in Hospital and Ambulatory Medical Care Facilities: Polish Results of the European I-MOVE+ Multicenter Study. *Adv Exp Med Biol*. 2017;1023:93–100.
213. Pebody R, Warburton F, Ellis J, Andrews N, Potts A, Cottrell S, et al. End-of-season influenza vaccine effectiveness in adults and children, United Kingdom, 2016/17. *Euro Surveill*. 2017;22(44):pii=17-00306.
214. Poehling KA, Caspard H, Peters TR, Belongia EA, Congeni B, Gaglani M, et al. 2015–2016 Vaccine Effectiveness of Live Attenuated and Inactivated Influenza Vaccines in Children in the United States. *Clin Infect Dis*. 2017;66(5):665–72.
215. Puig-Barbera J, Mira-Iglesias A, Tortajada-Girbes M, Lopez-Labrador FX, Librero-Lopez J, Diez-Domingo J, et al. Waning protection of influenza vaccination during four influenza seasons, 2011/2012 to 2014/2015. *Vaccine*. 2017;35(43):5799–807. [PubMed: 28941618]
216. Rondy M, Larrauri A, Casado I, Alfonsi V, Pitigoi D, Launay O, et al. 2015/16 seasonal vaccine effectiveness against hospitalisation with influenza A(H1N1)pdm09 and B among elderly people in Europe: results from the I-MOVE+ project. *Euro Surveill*. 2017;22(30):pii=30580.
217. Rondy M, Launay O, Castilla J, Costanzo S, Puig-Barbera J, Gefenaite G, et al. Repeated seasonal influenza vaccination among elderly in Europe: Effects on laboratory confirmed hospitalised influenza. *Vaccine*. 2017;35(34):4298–306. [PubMed: 28709555]
218. Saito N, Komori K, Suzuki M, Morimoto K, Kishikawa T, Yasaka T, et al. Negative impact of prior influenza vaccination on current influenza vaccination among people infected and not infected in prior season: A test-negative case–control study in Japan. *Vaccine*. 2017;35(4):687–93. [PubMed: 28043738]
219. Seki Y, Onose A, Sugaya N. Influenza vaccine effectiveness in adults based on the rapid influenza diagnostic test results, during the 2015/16 season. *J Infect Chemother*. 2017;23(9):615–20. [PubMed: 28668446]
220. Skowronski DM, Chambers C, De Serres G, Sabaiduc S, Winter AL, Dickinson JA, et al. Serial Vaccination and the Antigenic Distance Hypothesis: Effects on Influenza Vaccine Effectiveness During A(H3N2) Epidemics in Canada, 2010–2011 to 2014–2015. *J Infect Dis*. 2017;215(7):1059–99. [PubMed: 28180277]
221. Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Winter AL, Dickinson JA, et al. Beyond antigenic match: possible agent-host and immuno-epidemiological influences on influenza vaccine effectiveness during the 2015–16 season in Canada. *J Infect Dis*. 2017;216(12):1487–500. [PubMed: 29029166]
222. Skowronski DM, Chambers C, Sabaiduc S, Dickinson JA, Winter AL, De Serres G, et al. Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017. *Euro Surveill*. 2017;22(6):pii=30460.
223. Souty C, Vilcu AM, Capai L, van der Werf S, Valette M, Blanchon T, et al. Early estimates of 2016/17 seasonal influenza vaccine effectiveness in primary care in France. *J Clin Virol*. 2017;95:1–4. [PubMed: 28818690]
224. Trebbien R, Fischer TK, Krause TG, Nielsen L, Nielsen XC, Weinreich LS, et al. Changes in genetically drifted H3N2 influenza A viruses and vaccine effectiveness in adults 65 years and older during the 2016/17 season in Denmark. *J Clin Virol*. 2017;94:1–7. [PubMed: 28697450]
225. Valdin HL, Begue RE. Influenza vaccines effectiveness 2013–14 through 2015–16, a test-negative study in children. *Vaccine*. 2017;35(33):4088–93. [PubMed: 28669621]
226. van Doorn E, Darvishian M, Dijkstra F, Donker GA, Overduin P, Meijer A, et al. Influenza vaccine effectiveness estimates in the Dutch population from 2003 to 2014: The test-negative design case–control study with different control groups. *Vaccine*. 2017;35(21):2831–9. [PubMed: 28412077]



227. Vilcu AM, Souty C, Enouf V, Capai L, Turbelin C, Masse S, et al. Estimation of seasonal influenza vaccine effectiveness using data collected in primary care in France: comparison of the test-negative design and the screening method. *Clin Microbiol Infect.* 2017;24(4):431.e5–e12.
228. Zhang Y, Wu P, Feng L, Yang P, Pan Y, Feng S, et al. Influenza vaccine effectiveness against influenza-associated hospitalization in 2015/16 season, Beijing, China. *Vaccine.* 2017;35(23):3129–34. [PubMed: 28456530]
229. Anderson KB, Simasathien S, Watanaveeradej V, Weg AL, Ellison DW, Suwanpakdee D, et al. Clinical and laboratory predictors of influenza infection among individuals with influenza-like illness presenting to an urban Thai hospital over a five-year period. *PLoS One.* 2018;13(3):e0193050. [PubMed: 29513698]
230. Andrew MK, Shinde V, Hatchette T, Ambrose A, Boivin G, Bowie W, et al. Influenza vaccine effectiveness against influenza-related hospitalization during a season with mixed outbreaks of four influenza viruses: a test-negative case–control study in adults in Canada. *BMC Infect Dis.* 2017;17(1):805. [PubMed: 29284435]
231. Buchan SA, Chung H, Campitelli MA, Crowcroft NS, Gubbay JB, Karnauchow T, et al. Vaccine effectiveness against laboratory-confirmed influenza hospitalizations among young children during the 2010–11 to 2013–14 influenza seasons in Ontario, Canada. *PLoS One.* 2017;12(11):e0187834. [PubMed: 29149183]
232. Castilla J, Martinez-Baz I, Navascues A, Casado I, Aguinaga A, Diaz-Gonzalez J, et al. Comparison of influenza vaccine effectiveness in preventing outpatient and inpatient influenza cases in older adults, northern Spain, 2010/11 to 2015/16. *Euro Surveill.* 2018;23(2):pii=16–00780.
233. Chiu SS, Kwan MYW, Feng S, Wong JSC, Leung CW, Chan ELY, et al. Influenza vaccine effectiveness against influenza A(H3N2) hospitalizations in children in Hong Kong in a prolonged season, 2016/17. *J Infect Dis.* 2018;217(9):1365–71. [PubMed: 29346614]
234. Flannery B, Smith C, Garten RJ, Levine MZ, Chung JR, Jackson ML, et al. Influence of Birth Cohort on Effectiveness of 2015–2016 Influenza Vaccine Against Medically Attended Illness Due to 2009 Pandemic Influenza A(H1N1) Virus in the United States. *J Infect Dis.* 2018;218(2):189–96. [PubMed: 29361005]
235. Puig-Barbera J, Guglieri-Lopez B, Tortajada-Girbes M, Lopez-Labrador FX, Carballido-Fernandez M, Mollar-Maseres J, et al. Low influenza vaccine effectiveness and the effect of previous vaccination in preventing admission with A(H1N1)pdm09 or B/Victoria-Lineage in patients 60 years old or older during the 2015/2016 influenza season. *Vaccine.* 2017;35(52):7331–8. [PubMed: 29128380]
236. Kissling E, Valenciano M, Pozo F, Vilcu AM, Reuss A, Rizzo C, et al. 2015/16 I-MOVE/I-MOVE + multicentre case control study in Europe: moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage mismatched influenza B among children. *Influenza Other Respir Viruses.* 2017;12(4):423–37.
237. Mohl A, Grafe L, Helmeke C, Ziehm D, Monazahian M, Irmscher HM, et al. Estimating vaccine effectiveness against laboratory-confirmed influenza among children and adolescents in Lower Saxony and Saxony-Anhalt, 2012–2016. *Epidemiol Infect.* 2017;146(1):78–88. [PubMed: 29208075]
238. Mira-Iglesias A, Lopez-Labrador FX, Guglieri-Lopez B, Tortajada-Girbes M, Baselga-Moreno V, Cano L, et al. Influenza vaccine effectiveness in preventing hospitalisation of individuals 60 years of age and over with laboratory-confirmed influenza, Valencia Region, Spain, influenza season 2016/17. *Euro Surveill.* 2018;23(8):pii=17–00318.
239. Nichols MK, Andrew MK, Hatchette TF, Ambrose A, Boivin G, Bowie W, et al. Influenza vaccine effectiveness to prevent influenza-related hospitalizations and serious outcomes in Canadian adults over the 2011/12 through 2013/14 influenza seasons: A pooled analysis from the Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS Network). *Vaccine.* 2018;36(16):2166–75. [PubMed: 29548608]
240. Saito N, Komori K, Suzuki M, Kishikawa T, Yasaka T, Ariyoshi K. Dose-Dependent Negative Effects of Prior Multiple Vaccinations against Influenza A and Influenza B among School Children: A Study of Kamigoto Island in Japan during the 2011/12, 2012/13 and 2013/14 Influenza Seasons. *Clin Infect Dis.* 2018;67(6):897–904. [PubMed: 29528389]

241. Stein Y, Mandelboim M, Sefty H, Pando R, Mendelson E, Shohat T, et al. Seasonal influenza vaccine effectiveness in preventing laboratory-confirmed influenza in primary care in Israel 2016–2017 season: insights into novel age-specific analysis. *Clin Infect Dis*. 2017;66(9):1383–91.
242. Sugaya N, Shinjoh M, Nakata Y, Tsunematsu K, Yamaguchi Y, Komiyama O, et al. Three-season effectiveness of inactivated influenza vaccine in preventing influenza illness and hospitalization in children in Japan, 2013–2016. *Vaccine*. 2018;36(8):1063–71. [PubMed: 29361343]
243. Suzuki M, Katsurada N, L MN, Kaneko N, Yaegashi M, Hosokawa N, et al. Effectiveness of inactivated influenza vaccine against laboratory-confirmed influenza pneumonia among adults aged  $\geq 65$  years in Japan. *Vaccine*. 2018;36(21):2960–7. [PubMed: 29685596]
244. Valenciano M, Kissling E, Larrauri A, Nunes B, Pitigoi D, O'Donnell J, et al. Exploring the effect of previous inactivated influenza vaccination on seasonal influenza vaccine effectiveness against medically attended influenza: Results of the European I-MOVE multicentre test-negative case-control study, 2011/2012–2016/2017. *Influenza Other Respir Viruses*. 2018;12(5):567–81. [PubMed: 29659149]
245. Yaron-Yakoby H, Sefty H, Pando R, Dichtiar R, Katz MA, Stein Y, et al. Effectiveness of influenza vaccine in preventing medically-attended influenza virus infection in primary care, Israel, influenza seasons 2014/15 and 2015/16. *Euro Surveill*. 2018;23(7):pii=17–00026.
246. Yeung KHT, Chan KCC, Chan PKS, Lam DSY, Sham PCO, Yau YS, et al. Influenza vaccine effectiveness in hospitalised Hong Kong children: Feasibility of estimates from routine surveillance data. *Vaccine*. 2018;36(24):3477–85. [PubMed: 29739719]
247. Zhang L, Pan Y, M C, Duan W, Sun Y, W S, et al. Moderate influenza vaccine effectiveness against influenza A(H1N1)pdm09 virus and low effectiveness against A(H3N2) virus among older adults during 2013–2014 influenza season in Beijing, China. *Hum Vaccin Immunother*. 2018;14(6):1323–30. [PubMed: 29461909]
248. Castilla J, Ncas A, Casado I, Pcar-Gca A, Aguinaga A, Ezpeleta G, et al. Interim effectiveness of trivalent influenza vaccine in a season dominated by lineage mismatched influenza B, northern Spain, 2017/18. *Euro Surveill*. 2018;23(7):pii=18–00057.
249. Chiu SS, Kwan MYW, Feng S, Wong JSC, Leung CW, Chan ELY, et al. Interim estimate of influenza vaccine effectiveness in hospitalised children, Hong Kong, 2017/18. *Euro Surveill*. 2018;23(8):pii=18–00062.
250. Rondy M, Kissling E, Emborg HD, Gherasim A, Pebody R, Trebbien R, et al. Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies. *Euro Surveill*. 2018;23(9):pii=18–00086.
251. Skowronski DM, Chambers C, De Serres G, Dickinson JA, Winter AL, Hickman R, et al. Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018. *Euro Surveill*. 2018;23(5):pii=18–00035.
252. Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Winter AL, Dickinson JA, et al. Integrated Sentinel Surveillance Linking Genetic, Antigenic, and Epidemiologic Monitoring of Influenza Vaccine-Virus Relatedness and Effectiveness During the 2013–2014 Influenza Season. *J Infect Dis*. 2015;212(5):726–39. [PubMed: 25784728]
253. Pitigoi D, Ivanciuc AE, Necula G, Lupulescu E, Alexandrescu V, Savulescu C. Influenza vaccine effectiveness to prevent medically attended laboratory confirmed influenza during season 2010–2011 in Romania: a case control study. *Rev Romana Med Lab*. 2012;20(2):127–34.
254. McLean HQ, Thompson MG, Sundaram ME, Meece JK, McClure DL, Friedrich TC, et al. Impact of repeated vaccination on vaccine effectiveness against influenza A(H3N2) and B during 8 seasons. *Clin Infect Dis*. 2014;59(10):1375–85. [PubMed: 25270645]
255. Simona C, Katleen DGD, Lara C, Olivieri M, Rosaria S, Maurizio S, et al. Assessment of seasonal influenza vaccine effectiveness in patients from a central Italy reference hospital: pitfalls and intricacies from a pilot case-control study. *Epidemiol Biostat Public Health*. 2014;11(3).
256. Pitigoi D, Necula G, Alexandrescu V, Mihai ME, Cherciu CM, Tecu C, et al. Circulating influenza viruses and the effectiveness of seasonal influenza vaccine in Romania, season 2012–2013. *Rev Romana Med Lab*. 2015;23(1):9–20.

257. Chung JR, Flannery B, Thompson MG, Gaglani M, Jackson ML, Monto AS, et al. Seasonal Effectiveness of Live Attenuated and Inactivated Influenza Vaccine. *Pediatrics*. 2016;137(2):e20153279. [PubMed: 26738884]
258. Cowling BJ, Feng S, Finelli L, Steffens A, Fowlkes A. Assessment of influenza vaccine effectiveness in a sentinel surveillance network 2010–13, United States. *Vaccine*. 2016;34(1):61–6. [PubMed: 26611200]
259. Sullivan SG, Carville KS, Chilver M, Fielding JE, Grant KA, Kelly H, et al. Pooled influenza vaccine effectiveness estimates for Australia, 2012–2014. *Epidemiol Infect*. 2016;144(11):2317–28. [PubMed: 27125368]
260. Sullivan SG, Tay EL, Kelly H. Variable definitions of the influenza season and their impact on vaccine effectiveness estimates. *Vaccine*. 2013;31(40):4280–3. [PubMed: 23850417]
261. Radin JM, Hawksworth AW, Myers CA, Ricketts MN, Hansen EA, Brice GT. Influenza vaccine effectiveness: Maintained protection throughout the duration of influenza seasons 2010–2011 through 2013–2014. *Vaccine*. 2016;34(33):3907–12. [PubMed: 27265447]
262. Rondy M, Gherasim A, Casado I, Launay O, Rizzo C, Pitigoi D, et al. Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly: awareness warranted for 2017/18 season. *Euro Surveill*. 2017;22(41):pii=17–00645.
263. Ando S Effectiveness of quadrivalent influenza vaccine based on the test-negative control study in children during the 2016–2017 season. *J Infect Chemother*. 2018;24(10):782–8. [PubMed: 29945763]
264. Blyth CC, Macartney KK, McRae J, Clark JE, Marshall HS, Buttery J, et al. Influenza Epidemiology, Vaccine Coverage and Vaccine Effectiveness in Children Admitted to Sentinel Australian Hospitals in 2017: Results from the PAEDS-FluCAN Collaboration. *Clin Infect Dis*. 2018 (in press).
265. Buchan SA, Booth S, Scott AN, Simmonds KA, Svenson LW, Drews SJ, et al. Effectiveness of Live Attenuated vs Inactivated Influenza Vaccines in Children During the 2012–2013 Through 2015–2016 Influenza Seasons in Alberta, Canada: A Canadian Immunization Research Network (CIRN) Study. *JAMA Pediatr*. 2018;172(9):e181514. [PubMed: 29971427]
266. Chakhunashvili G, Wagner AL, Power LE, Janusz CB, Machablashvili A, Karseladze I, et al. Severe Acute Respiratory Infection (SARI) sentinel surveillance in the country of Georgia, 2015–2017. *PLoS One*. 2018;13(7):e0201497. [PubMed: 30059540]
267. Chan YD, Wong ML, Au KW, Chuang SK. Seasonal influenza vaccine effectiveness at primary care level, Hong Kong SAR, 2017/2018 winter. *Hum Vaccin Immunother*. 2018 (in press).
268. Flannery B, Chung JR, Monto AS, Martin ET, Belongia EA, McLean HQ, et al. Influenza Vaccine Effectiveness in the United States during the 2016–2017 Season. *Clin Infect Dis*. 2018 (in press).
269. Kimiya T, Shinjoh M, Anzo M, Takahashi H, Sekiguchi S, Sugaya N, et al. Effectiveness of inactivated quadrivalent influenza vaccine in the 2015/2016 season as assessed in both a test-negative case–control study design and a traditional case–control study design. *Eur J Pediatr*. 2018;177(7):1009–17. [PubMed: 29680993]
270. Machado A, Kislaya I, Nunes B, Rodrigues AP, Guiomar R, Euro EVAP. Moderate influenza vaccine effectiveness in a B mismatch season: Preliminary results from the 2017/2018 season in Portugal. *Pulmonology*. 2018;24(4):260–2. [PubMed: 29903599]
271. Pebody RG, Warburton F, Andrews N, Sinnathamby M, Yonova I, Reynolds A, et al. Uptake and effectiveness of influenza vaccine in those aged 65 years and older in the United Kingdom, influenza seasons 2010/11 to 2016/17. *Euro Surveill*. 2018;23(39):pii=1800092.
272. Seki Y, Onose A, Murayama T, Koide C, Sugaya N. Influenza vaccine showed a good preventive effect against influenza-associated hospitalization among elderly patients, during the 2016/17 season in Japan. *J Infect Chemother*. 2018;24(11):873–80. [PubMed: 30100400]
273. Shinjoh M, Sugaya N, Yamaguchi Y, Iibuchi N, Kamimaki I, Goto A, et al. Inactivated influenza vaccine effectiveness and an analysis of repeated vaccination for children during the 2016/17 season. *Vaccine*. 2018;36(37):5510–8. [PubMed: 30093289]
274. Tam YH, Ng TWY, Chu DKW, Fang VJ, Cowling BJ, Malik Peiris JS, et al. The effectiveness of influenza vaccination against medically-attended illnesses in Hong Kong across three years with

- different degrees of vaccine match, 2014–17. *Vaccine*. 2018;36(41):6117–23. [PubMed: 30190121]
275. Thompson MG, Kwong JC, Regan AK, Katz MA, Drews SJ, Azziz-Baumgartner E, et al. Influenza Vaccine Effectiveness in Preventing Influenza-associated Hospitalizations During Pregnancy: A Multi-country Retrospective Test Negative Design Study, 2010–2016. *Clin Infect Dis*. 2018 (in press).
276. Thompson MG, Pierse N, Sue Huang Q, Prasad N, Duque J, Claire Newbern E, et al. Influenza vaccine effectiveness in preventing influenza-associated intensive care admissions and attenuating severe disease among adults in New Zealand 2012–2015. *Vaccine*. 2018;36(39): 5916–25. [PubMed: 30077480]
277. Wu S, Pan Y, Zhang X, Zhang L, Duan W, Ma C, et al. Influenza vaccine effectiveness in preventing laboratory-confirmed influenza in outpatient settings: A test-negative case-control study in Beijing, China, 2016/17 season. *Vaccine*. 2018;36(38):5774–80. [PubMed: 30087046]
278. Zhang L, Pan Y, Hackert V, van der Hoek W, Meijer A, Krafft T, et al. The 2015–2016 influenza epidemic in Beijing, China: Unlike elsewhere, circulation of influenza A(H3N2) with moderate vaccine effectiveness. *Vaccine*. 2018;36(33):4993–5001. [PubMed: 30017144]
279. Abeid KA, Jani B, Cortese MM, Kamugisha C, Mwenda JM, Pandu AS, et al. Monovalent Rotavirus Vaccine Effectiveness and Impact on Rotavirus Hospitalizations in Zanzibar, Tanzania: Data From the First 3 Years After Introduction. *J Infect Dis*. 2017;215(2):183–91. [PubMed: 27815381]
280. Armah G, Pringle K, Enweronu-Laryea CC, Ansong D, Mwenda JM, Diamenu SK, et al. Impact and Effectiveness of Monovalent Rotavirus Vaccine Against Severe Rotavirus Diarrhea in Ghana. *Clin Infect Dis*. 2016;62 Suppl 2:S200–7. [PubMed: 27059357]
281. Bar-Zeev N, Jere KC, Bennett A, Pollock L, Tate JE, Nakagomi O, et al. Population Impact and Effectiveness of Monovalent Rotavirus Vaccination in Urban Malawian Children 3 Years After Vaccine Introduction: Ecological and Case-control Analyses. *Clin Infect Dis*. 2016;62 Suppl 2:S213–9. [PubMed: 27059359]
282. Bellido-Blasco JB, Sabater-Vidal S, Salvador-Ribera Mdel M, Arnedo-Pena A, Tirado-Balaguer MD, Meseguer-Ferrer N, et al. Rotavirus vaccination effectiveness: a case-case study in the EDICS project, Castellon (Spain). *Vaccine*. 2012;30(52):7536–40. [PubMed: 23103196]
283. Beres LK, Tate JE, Njobvu L, Chibwe B, Rudd C, Guffey MB, et al. A Preliminary Assessment of Rotavirus Vaccine Effectiveness in Zambia. *Clin Infect Dis*. 2016;62 Suppl 2:S175–82. [PubMed: 27059353]
284. Castilla J, Beristain X, Martinez-Artola V, Navascues A, Garcia Cenoz M, Alvarez N, et al. Effectiveness of rotavirus vaccines in preventing cases and hospitalizations due to rotavirus gastroenteritis in Navarre, Spain. *Vaccine*. 2012;30(3):539–43. [PubMed: 22122860]
285. Chang WC, Yen C, Wu FT, Huang YC, Lin JS, Huang FC, et al. Effectiveness of 2 rotavirus vaccines against rotavirus disease in Taiwanese infants. *Pediatr Infect Dis J*. 2014;33(3):e81–6. [PubMed: 24569388]
286. Correia JB, Patel MM, Nakagomi O, Montenegro FM, Germano EM, Correia NB, et al. Effectiveness of monovalent rotavirus vaccine (Rotarix) against severe diarrhea caused by serotypically unrelated G2P[4] strains in Brazil. *J Infect Dis*. 2010;201(3):363–9. [PubMed: 20047501]
287. Cortese MM, Immergluck LC, Held M, Jain S, Chan T, Grizas AP, et al. Effectiveness of monovalent and pentavalent rotavirus vaccine. *Pediatrics*. 2013;132(1):e25–33. [PubMed: 23776114]
288. Cortese MM, Leblanc J, White KE, Jerris RC, Stinchfield P, Preston KL, et al. Leveraging state immunization information systems to measure the effectiveness of rotavirus vaccine. *Pediatrics*. 2011;128(6):e1474–81. [PubMed: 22084328]
289. Cotes-Cantillo K, Paternina-Caicedo A, Coronell-Rodriguez W, Alvis-Guzman N, Parashar UD, Patel M, et al. Effectiveness of the monovalent rotavirus vaccine in Colombia: a case-control study. *Vaccine*. 2014;32(25):3035–40. [PubMed: 24699470]

290. Doll MK, Buckeridge DL, Morrison KT, Gagneur A, Tapiero B, Charest H, et al. Effectiveness of monovalent rotavirus vaccine in a high-income, predominant-use setting. *Vaccine*. 2015;33(51):7307–14. [PubMed: 26546262]
291. Donauer S, Payne DC, Edwards KM, Szilagyi PG, Hornung RW, Weinberg GA, et al. Determining the effectiveness of the pentavalent rotavirus vaccine against rotavirus hospitalizations and emergency department visits using two study designs. *Vaccine*. 2013;31(24):2692–7. [PubMed: 23583814]
292. Fujii Y, Noguchi A, Miura S, Ishii H, Nakagomi T, Nakagomi O, et al. Effectiveness of rotavirus vaccines against hospitalisations in Japan. *BMC Pediatr*. 2017;17(1):156. [PubMed: 28693503]
293. Gastanaduy PA, Contreras-Roldan I, Bernart C, Lopez B, Benoit SR, Xuya M, et al. Effectiveness of Monovalent and Pentavalent Rotavirus Vaccines in Guatemala. *Clin Infect Dis*. 2016;62 Suppl 2:S121–6. [PubMed: 27059345]
294. Gastanaduy PA, Steenhoff AP, Mokomane M, Esona MD, Bowen MD, Jibril H, et al. Effectiveness of Monovalent Rotavirus Vaccine After Programmatic Implementation in Botswana: A Multisite Prospective Case–control Study. *Clin Infect Dis*. 2016;62 Suppl 2:S161–7. [PubMed: 27059351]
295. Gheorghita S, Birca L, Donos A, Wasley A, Birca I, Cojocaru R, et al. Impact of Rotavirus Vaccine Introduction and Vaccine Effectiveness in the Republic of Moldova. *Clin Infect Dis*. 2016;62 Suppl 2:S140–6. [PubMed: 27059348]
296. Groome MJ, Page N, Cortese MM, Moyes J, Zar HJ, Kapongo CN, et al. Effectiveness of monovalent human rotavirus vaccine against admission to hospital for acute rotavirus diarrhoea in South African children: a case–control study. *Lancet Infect Dis*. 2014;14(11):1096–104. [PubMed: 25303843]
297. Hemming-Harlo M, Vesikari T, Uhari M, Renko M, Salminen M, Torcel-Pagnon L, et al. Sustained High Effectiveness of RotaTeq on Hospitalizations Attributable to Rotavirus-Associated Gastroenteritis During 4 Years in Finland. *J Pediatric Infect Dis Soc*. 2016;6(4):317–23.
298. Immergluck LC, Parker TC, Jain S, Laghaie E, Spandorfer P, Jerris RC, et al. Sustained Effectiveness of Monovalent and Pentavalent Rotavirus Vaccines in Children. *J Pediatr*. 2016;172:116–20.e1. [PubMed: 26935786]
299. Marlow R, Ferreira M, Cordeiro E, Trotter C, Januario L, Finn A, et al. Case control study of rotavirus vaccine effectiveness in Portugal during 6 years of private market use. *Pediatr Infect Dis J*. 2015;34(5):509–12. [PubMed: 25551832]
300. Mast TC, Khawaja S, Espinoza F, Paniagua M, Del Carmen LP, Cardellino A, et al. Case–control study of the effectiveness of vaccination with pentavalent rotavirus vaccine in Nicaragua. *Pediatr Infect Dis J*. 2011;30(11):e209–15. [PubMed: 21768920]
301. Mohammed A, Immergluck L, Parker TC, Jain S, Leong T, Anderson EJ, et al. Association between mixed rotavirus vaccination types of infants and rotavirus acute gastroenteritis. *Vaccine*. 2015;33(42):5670–7. [PubMed: 26322843]
302. Muhsen K, Anis E, Rubinstein U, Kassem E, Goren S, Shulman LM, et al. Effectiveness of rotavirus pentavalent vaccine under a universal immunization programme in Israel, 2011–2015: a case–control study. *Clin Microbiol Infect*. 2017;24(1):53–9. [PubMed: 28442435]
303. Muhsen K, Shulman L, Kasem E, Rubinstein U, Shachter J, Kremer A, et al. Effectiveness of rotavirus vaccines for prevention of rotavirus gastroenteritis-associated hospitalizations in Israel: a case–control study. *Hum Vaccin*. 2010;6(6):450–4. [PubMed: 20448471]
304. Patel M, Pedreira C, De Oliveira LH, Tate J, Leshem E, Mercado J, et al. Effectiveness of Pentavalent Rotavirus Vaccine Against a Diverse Range of Circulating Strains in Nicaragua. *Clin Infect Dis*. 2016;62 Suppl 2:S127–32. [PubMed: 27059346]
305. Patel M, Pedreira C, De Oliveira LH, Umama J, Tate J, Lopman B, et al. Duration of protection of pentavalent rotavirus vaccination in Nicaragua. *Pediatrics*. 2012;130(2):e365–72. [PubMed: 22753550]
306. Patel MM, Patzi M, Pastor D, Nina A, Roca Y, Alvarez L, et al. Effectiveness of monovalent rotavirus vaccine in Bolivia: case–control study. *BMJ*. 2013;346:f3726. [PubMed: 23783434]



307. Platts-Mills JA, Amour C, Gratz J, Nshama R, Walongo T, Mujaga B, et al. Impact of rotavirus vaccine introduction and post-introduction etiology of diarrhea requiring hospital admission in Haydom, Tanzania, a rural African setting. *Clin Infect Dis*. 2017;65(7):1144–51. [PubMed: 28575304]
308. Pringle KD, Patzi M, Tate JE, Iniguez Rojas V, Patel M, Inchauste Jordan L, et al. Sustained Effectiveness of Rotavirus Vaccine Against Very Severe Rotavirus Disease Through the Second Year of Life, Bolivia 2013–2014. *Clin Infect Dis*. 2016;62 Suppl 2:S115–20. [PubMed: 27059344]
309. Sahakyan G, Grigoryan S, Wasley A, Mosina L, Sargsyan S, Asoyan A, et al. Impact and Effectiveness of Monovalent Rotavirus Vaccine in Armenian Children. *Clin Infect Dis*. 2016;62 Suppl 2:S147–54. [PubMed: 27059349]
310. Sahni LC, Boom JA, Patel MM, Baker CJ, Rench MA, Parashar UD, et al. Use of an immunization information system to assess the effectiveness of pentavalent rotavirus vaccine in US children. *Vaccine*. 2010;28(38):6314–7. [PubMed: 20637764]
311. Snelling TL, Andrews RM, Kirkwood CD, Culvenor S, Carapetis JR. Case–control evaluation of the effectiveness of the G1P[8] human rotavirus vaccine during an outbreak of rotavirus G2P[4] infection in central Australia. *Clin Infect Dis*. 2011;52(2):191–9. [PubMed: 21288843]
312. Staat MA, Payne DC, Donauer S, Weinberg GA, Edwards KM, Szilagyi PG, et al. Effectiveness of pentavalent rotavirus vaccine against severe disease. *Pediatrics*. 2011;128(2):e267–75. [PubMed: 21768317]
313. Tate JE, Mijatovic-Rustempasic S, Tam KI, Lyde FC, Payne DC, Szilagyi P, et al. Comparison of 2 assays for diagnosing rotavirus and evaluating vaccine effectiveness in children with gastroenteritis. *Emerg Infect Dis*. 2013;19(8):1245–52. [PubMed: 23876518]
314. Tate JE, Ngabo F, Donnen P, Gatera M, Uwimana J, Rugambwa C, et al. Effectiveness of Pentavalent Rotavirus Vaccine Under Conditions of Routine Use in Rwanda. *Clin Infect Dis*. 2016;62 Suppl 2:S208–12. [PubMed: 27059358]
315. Yeung KHT, Tate JE, Chan CC, Chan MCW, Chan PKS, Poon KH, et al. Rotavirus vaccine effectiveness in Hong Kong children. *Vaccine*. 2016;34(41):4935–42. [PubMed: 27595446]
316. Boom JA, Tate JE, Sahni LC, Rench MA, Quaye O, Mijatovic-Rustempasic S, et al. Sustained protection from pentavalent rotavirus vaccination during the second year of life at a large, urban United States pediatric hospital. *Pediatr Infect Dis J*. 2010;29(12):1133–5. [PubMed: 20634776]
317. Leshem E, Givon-Lavi N, Tate JE, Greenberg D, Parashar UD, Dagan R. Real-World Effectiveness of Pentavalent Rotavirus Vaccine Among Bedouin and Jewish Children in Southern Israel. *Clin Infect Dis*. 2016;62 Suppl 2:S155–60. [PubMed: 27059350]
318. Martinon-Torres F, Bouzon Alejandro M, Redondo Collazo L, Sanchez Lastres JM, Pertega Diaz S, Seoane Pillado MT, et al. Effectiveness of rotavirus vaccination in Spain. *Hum Vaccin*. 2011;7(7):757–61. [PubMed: 21521947]
319. Payne DC, Boom JA, Staat MA, Edwards KM, Szilagyi PG, Klein EJ, et al. Effectiveness of pentavalent and monovalent rotavirus vaccines in concurrent use among US children <5 years of age, 2009–2011. *Clin Infect Dis*. 2013;57(1):13–20. [PubMed: 23487388]
320. Payne DC, Selvarangan R, Azimi PH, Boom JA, Englund JA, Staat MA, et al. Long-term Consistency in Rotavirus Vaccine Protection: RV5 and RV1 Vaccine Effectiveness in US Children, 2012–2013. *Clin Infect Dis*. 2015;61(12):1792–9. [PubMed: 26449565]
321. Vesikari T, Uhari M, Renko M, Hemming M, Salminen M, Torcel-Pagnon L, et al. Impact and effectiveness of RotaTeq(R) vaccine based on 3 years of surveillance following introduction of a rotavirus immunization program in Finland. *Pediatr Infect Dis J*. 2013;32(12):1365–73. [PubMed: 24051998]
322. Jani B, Hokororo A, Mchomvu J, Cortese MM, Kamugisha C, Mujuni D, et al. Detection of rotavirus before and after monovalent rotavirus vaccine introduction and vaccine effectiveness among children in mainland Tanzania. *Vaccine*. 2018 (in press).
323. Mokomane M, Tate JE, Steenhoff AP, Esona MD, Bowen MD, Lechiile K, et al. Evaluation of the Influence of Gastrointestinal Co-Infections on Rotavirus Vaccine Effectiveness in Botswana. *Pediatr Infect Dis J*. 2017;37(3):e58–e62.



324. Araki K, Hara M, Shimanoe C, Nishida Y, Matsuo M, Tanaka K. Case-control Study of Rotavirus Vaccine Effectiveness Compared to Test-Negative Controls or Hospital Controls. *J Epidemiol.* 2018 (in press).
325. Araki K, Hara M, Tsugawa T, Shimanoe C, Nishida Y, Matsuo M, et al. Effectiveness of monovalent and pentavalent rotavirus vaccines in Japanese children. *Vaccine.* 2018;36(34):5187–93. [PubMed: 30037664]
326. Lopez AL, Daag JV, Esparagoza J, Bonifacio J, Fox K, Nyambat B, et al. Effectiveness of monovalent rotavirus vaccine in the Philippines. *Sci Rep.* 2018;8(1):14291. [PubMed: 30250267]
327. Andrews N, Waight PA, Borrow R, Ladhani S, George RC, Slack MP, et al. Using the indirect cohort design to estimate the effectiveness of the seven valent pneumococcal conjugate vaccine in England and Wales. *PLoS One.* 2011;6(12):e28435. [PubMed: 22164292]
328. Andrews NJ, Waight PA, Burbidge P, Pearce E, Roalfe L, Zancolli M, et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. *Lancet Infect Dis.* 2014;14(9):839–46. [PubMed: 25042756]
329. Andrews NJ, Waight PA, George RC, Slack MP, Miller E. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. *Vaccine.* 2012;30(48):6802–8. [PubMed: 23000122]
330. Andrews RM, Counahan ML, Hogg GG, McIntyre PB. Effectiveness of a publicly funded pneumococcal vaccination program against invasive pneumococcal disease among the elderly in Victoria, Australia. *Vaccine.* 2004;23(2):132–8. [PubMed: 15531029]
331. Benin AL, O'Brien KL, Watt JP, Reid R, Zell ER, Katz S, et al. Effectiveness of the 23-valent polysaccharide vaccine against invasive pneumococcal disease in Navajo adults. *J Infect Dis.* 2003;188(1):81–9. [PubMed: 12825175]
332. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. *JAMA.* 1993;270(15):1826–31. [PubMed: 8411526]
333. De Serres G, Pilishvili T, Link-Gelles R, Reingold A, Gershman K, Petit S, et al. Use of surveillance data to estimate the effectiveness of the 7-valent conjugate pneumococcal vaccine in children less than 5 years of age over a 9 year period. *Vaccine.* 2012;30(27):4067–72. [PubMed: 22525797]
334. Gutierrez Rodriguez MA, Ordobas Gavin MA, Garcia-Comas L, Sanz Moreno JC, Cordoba Deorador E, Lasheras Carbajo MD, et al. Effectiveness of 23-valent pneumococcal polysaccharide vaccine in adults aged 60 years and over in the Region of Madrid, Spain, 2008–2011. *Euro Surveill.* 2014;19(40):pii=20922.
335. Latasa P, Ordobas M, Garrido-Esteba M, Gil de Miguel A, Sanz JC, Barranco MD, et al. Effectiveness of different vaccine schedules for heptavalent and 13-valent conjugate vaccines against pneumococcal disease in the Community of Madrid. *Vaccine.* 2017;35(40):5381–7. [PubMed: 28807606]
336. Moberley S, Krause V, Cook H, Mulholland K, Carapetis J, Torzillo P, et al. Failure to vaccinate or failure of vaccine? Effectiveness of the 23-valent pneumococcal polysaccharide vaccine program in Indigenous adults in the Northern Territory of Australia. *Vaccine.* 2010;28(11):2296–301. [PubMed: 20116468]
337. Mooney JD, Weir A, McMenamin J, Ritchie LD, Macfarlane TV, Simpson CR, et al. The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004. *BMC Infect Dis.* 2008;8:53. [PubMed: 18433473]
338. Ochoa-Gondar O, Figuerola-Massana E, Vila-Corcoles A, Aguirre CA, de Diego C, Satue E, et al. Epidemiology of *Streptococcus pneumoniae* causing acute otitis media among children in Southern Catalonia throughout 2007–2013: Incidence, serotype distribution and vaccine's effectiveness. *Int J Pediatr Otorhinolaryngol.* 2015;79(12):2104–8. [PubMed: 26453272]
339. Olarte L, Lin PL, Barson WJ, Romero JR, Tan TQ, Givner LB, et al. Invasive pneumococcal infections in children following transplantation in the pneumococcal conjugate vaccine era. *Transpl Infect Dis.* 2017;19(1).

340. Ruckinger S, van der Linden M, Reinert RR, von Kries R. Efficacy of 7-valent pneumococcal conjugate vaccination in Germany: An analysis using the indirect cohort method. *Vaccine*. 2010;28(31):5012–6. [PubMed: 20546832]
341. Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margolis A, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. *N Engl J Med*. 1991;325(21):1453–60. [PubMed: 1944423]
342. Singleton RJ, Butler JC, Bulkow LR, Hurlburt D, O'Brien KL, Doan W, et al. Invasive pneumococcal disease epidemiology and effectiveness of 23-valent pneumococcal polysaccharide vaccine in Alaska native adults. *Vaccine*. 2007;25(12):2288–95. [PubMed: 17254673]
343. Suzuki M, Dhoubhadel BG, Ishifuji T, Yasunami M, Yaegashi M, Asoh N, et al. Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study. *Lancet Infect Dis*. 2017;17(3):313–21. [PubMed: 28126327]
344. van der Linden M, Falkenhorst G, Perniciaro S, Fitzner C, Imohl M. Effectiveness of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) against Invasive Pneumococcal Disease among Children under Two Years of Age in Germany. *PLoS One*. 2016;11(8):e0161257. [PubMed: 27526117]
345. Verani JR, Domingues CM, de Moraes JC. Indirect cohort analysis of 10-valent pneumococcal conjugate vaccine effectiveness against vaccine-type and vaccine-related invasive pneumococcal disease. *Vaccine*. 2015;33(46):6145–8. [PubMed: 26469718]
346. Wiemken TL, Carrico RM, Klein SL, Jonsson CB, Peyrani P, Kelley RR, et al. The effectiveness of the polysaccharide pneumococcal vaccine for the prevention of hospitalizations due to *Streptococcus pneumoniae* community-acquired pneumonia in the elderly differs between the sexes: results from the Community-Acquired Pneumonia Organization (CAPO) international cohort study. *Vaccine*. 2014;32(19):2198–203. [PubMed: 24613522]
347. Jayasinghe S, Chiu C, Quinn H, Menzies R, Gilmour R, McIntyre P. Effectiveness of 7- and 13-Valent Pneumococcal Conjugate Vaccines in a Schedule without a Booster dose: a 10-Year Observational Study. *Clin Infect Dis*. 2018;67(3):367–74. [PubMed: 29471432]
348. Prato R, Fortunato F, Cappelli MG, Chironna M, Martinelli D. Effectiveness of the 13-valent pneumococcal conjugate vaccine against adult pneumonia in Italy: a case–control study in a 2-year prospective cohort. *BMJ Open*. 2018;8(3):e019034.
349. McLaughlin JM, Jiang Q, Isturiz RE, Sings HL, Swerdlow DL, Gessner BD, et al. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design. *Clin Infect Dis*. 2018;67(10):1498–506. [PubMed: 29790925]
350. Baxter R, Bartlett J, Rowhani-Rahbar A, Fireman B, Klein NP. Effectiveness of pertussis vaccines for adolescents and adults: case–control study. *BMJ*. 2013;347:f4249. [PubMed: 23873919]
351. Klein NP, Bartlett J, Fireman B, Aukes L, Buck PO, Krishnarajah G, et al. Waning protection following 5 doses of a 3-component diphtheria, tetanus, and acellular pertussis vaccine. *Vaccine*. 2017;35(26):3395–400. [PubMed: 28506516]
352. Klein NP, Bartlett J, Fireman B, Rowhani-Rahbar A, Baxter R. Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers. *Pediatrics*. 2013;131(6):e1716–22. [PubMed: 23690518]
353. Schwartz KL, Kwong JC, Deeks SL, Campitelli MA, Jamieson FB, Marchand-Austin A, et al. Effectiveness of pertussis vaccination and duration of immunity. *CMAJ*. 2016;188(16):E399–e406. [PubMed: 27672225]
354. Wolff G, Bell M, Escobar J, Ruiz S. Estimates of pertussis vaccine effectiveness in United States air force pediatric dependents. *Vaccine*. 2015;33(28):3228–33. [PubMed: 25957071]
355. Klein NP, Bartlett J, Rowhani-Rahbar A, Fireman B, Baxter R. Waning protection after fifth dose of acellular pertussis vaccine in children. *N Engl J Med*. 2012;367(11):1012–9. [PubMed: 22970945]

356. Ali M, You YA, Sur D, Kanungo S, Kim DR, Deen J, et al. Validity of the estimates of oral cholera vaccine effectiveness derived from the test-negative design. *Vaccine*. 2016;34(4):479–85. [PubMed: 26707378]
357. Franke MF, Jerome JG, Matias WR, Ternier R, Hilaire IJ, Harris JB, et al. Comparison of two control groups for estimation of oral cholera vaccine effectiveness using a case–control study design. *Vaccine*. 2017;35(43):5819–27. [PubMed: 28916247]
358. Azman AS, Parker LA, Rumunu J, Tadesse F, Grandesso F, Deng LL, et al. Effectiveness of one dose of oral cholera vaccine in response to an outbreak: a case-cohort study. *Lancet Glob Health*. 2016;4(11):e856–e63. [PubMed: 27765293]
359. Wierzbza TF, Kar SK, Mogasale VV, Kerketta AS, You YA, Baral P, et al. Effectiveness of an oral cholera vaccine campaign to prevent clinically-significant cholera in Odisha State, India. *Vaccine*. 2015;33(21):2463–9. [PubMed: 25850019]
360. Grassly NC, Wenger J, Durrani S, Bahl S, Deshpande JM, Sutter RW, et al. Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case–control study. *Lancet*. 2007;369(9570):1356–62. [PubMed: 17448821]
361. Jenkins HE, Aylward RB, Gasasira A, Donnelly CA, Abanida EA, Koleosho-Adelekan T, et al. Effectiveness of immunization against paralytic poliomyelitis in Nigeria. *N Engl J Med*. 2008;359(16):1666–74. [PubMed: 18923171]
362. Mahamud A, Kamadjeu R, Webeck J, Mbaeyi C, Baranyikwa MT, Birungi J, et al. Effectiveness of oral polio vaccination against paralytic poliomyelitis: a matched case–control study in Somalia. *J Infect Dis*. 2014;210 Suppl 1:S187–93. [PubMed: 25316835]
363. O'Reilly KM, Durry E, ul Islam O, Quddus A, Abid N, Mir TP, et al. The effect of mass immunisation campaigns and new oral poliovirus vaccines on the incidence of poliomyelitis in Pakistan and Afghanistan, 2001–11: a retrospective analysis. *Lancet*. 2012;380(9840):491–8. [PubMed: 22766207]
364. Morales D, Garcia-Cenoz M, Moreno L, Bernaola E, Barricarte A, Castilla J. Meningococcal C conjugate vaccine: Impact of a vaccination program and long-term effectiveness in Navarra, Spain, 2000–2014. *Enferm Infecc Microbiol Clin*. 2016;34(10):639–44. [PubMed: 26778101]
365. Noronha CP, Struchiner CJ, Halloran ME. Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case–control study. *Int J Epidemiol*. 1995;24(5):1050–7. [PubMed: 8557439]
366. Rivest P, Allard R. The effectiveness of serogroup C meningococcal vaccine estimated from routine surveillance data. *Vaccine*. 2002;20(19–20):2533–6. [PubMed: 12057609]
367. Doshi RH, Mukadi P, Shidi C, Mulumba A, Hoff NA, Gerber S, et al. Field evaluation of measles vaccine effectiveness among children in the Democratic Republic of Congo. *Vaccine*. 2015;33(29):3407–14. [PubMed: 25937449]
368. Yang Z, Xu J, Wang M, Di B, Tan H, He Q, et al. Measles epidemic from 1951 to 2012 and vaccine effectiveness in Guangzhou, southern China. *Hum Vaccin Immunother*. 2014;10(4):1091–6. [PubMed: 24513504]
369. Wagner KS, Freedman JL, Andrews NJ, Jones JA. Effectiveness of the typhoid Vi vaccine in overseas travelers from England. *J Travel Med*. 2015;22(2):87–93. [PubMed: 25444695]
370. Petousis-Harris H, Paynter J, Morgan J, Saxton P, McArdle B, Goodyear-Smith F, et al. Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case–control study. *Lancet*. 2017;390(10102):1603–10. [PubMed: 28705462]
371. Heard I, Tondeur L, Arowas L, Demazoin M, Falguières M, Parent Du Chatelet I. Effectiveness of Human Papillomavirus Vaccination on Prevalence of Vaccine Genotypes in Young Sexually Active Women in France. *J Infect Dis*. 2017;215(5):757–63. [PubMed: 28011911]
372. Lewis RF, Kisakye A, Gessner BD, Duku C, Odipio JB, Iriso R, et al. Action for child survival: elimination of *Haemophilus influenzae* type b meningitis in Uganda. *Bull World Health Organ*. 2008;86(4):292–301. [PubMed: 18438518]
373. Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. *Vaccine*. 2013;31(17):2165–8. [PubMed: 23499601]

374. Shi M, Ainslie KEC, Haber M, Orenstein WA. A comparison of the test-negative and the traditional case-control study designs for estimation of influenza vaccine effectiveness under nonrandom vaccination. *BMC Infect Dis*. 2017.
375. Ainslie KEC, Shi M, Haber M, Orenstein WA. On the bias of estimates of influenza vaccine effectiveness from test-negative studies. *Vaccine*. 2017.
376. Foppa IM, Haber M, Ferdinands JM, Shay DK. The case test-negative design for studies of the effectiveness of influenza vaccine. *Vaccine*. 2013;31(30):3104–9. [PubMed: 23624093]
377. Jackson ML, Phillips CH, Benoit J, Kiniry E, Madziwa L, Nelson JC, et al. The impact of selection bias on vaccine effectiveness estimates from test-negative studies. *Vaccine*. 2018;36(5):751–7. [PubMed: 29254838]
378. Jackson ML. Use of self-reported vaccination status can bias vaccine effectiveness estimates from test-negative studies. *Vaccine*. 2019 (in press).
379. World Health Organization. Pneumococcal vaccines: WHO position paper, 2012. *Wkly Epidemiol Rec*. 2012;14(87):129–44.
380. World Health Organization. Immunization, Vaccines and Biologicals: Vaccine Position Papers 2018 [Available from: <http://www.who.int/immunization/documents/positionpapers/en/>].
381. Lewnard JA, Tedijanto C, Cowling BJ, Lipsitch M. Measurement of Vaccine Direct Effects under the Test-Negative Design. *Am J Epidemiol*. 2018 (in press).
382. Kasper MR, Wierzba TF, Sovann L, Blair PJ, Putnam SD. Evaluation of an influenza-like illness case definition in the diagnosis of influenza among patients with acute febrile illness in Cambodia. *BMC Infect Dis*. 2010;10:320. [PubMed: 21054897]
383. Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. *Lancet*. 2006;368(9546):1495–502. [PubMed: 17071283]
384. Isturiz R, Sings HL, Hilton B, Arguedas A, Reinert RR, Jodar L. Streptococcus pneumoniae serotype 19A: worldwide epidemiology. *Expert Rev Vaccines*. 2017;16(10):1007–27. [PubMed: 28783380]
385. Hausdorff WP, Hoet B, Schuerman L. Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A? *BMC Pediatr*. 2010;10:4. [PubMed: 20122261]
386. Lewnard JA, Givon-Lavi N, Weinberger DM, Lipsitch M, Dagan R. Pan-serotype Reduction in Progression of Streptococcus pneumoniae to Otitis Media After Rollout of Pneumococcal Conjugate Vaccines. *Clin Infect Dis*. 2017;65(11):1853–61. [PubMed: 29020218]
387. Roca A, Hill PC, Townend J, Egere U, Antonio M, Bojang A, et al. Effects of community-wide vaccination with PCV-7 on pneumococcal nasopharyngeal carriage in the Gambia: a cluster-randomized trial. *PLoS Med*. 2011;8(10):e1001107. [PubMed: 22028630]
388. Nzenze SA, Shiri T, Nunes MC, Klugman KP, Kahn K, Twine R, et al. Temporal changes in pneumococcal colonization in a rural African community with high HIV prevalence following routine infant pneumococcal immunization. *Pediatr Infect Dis J*. 2013;32(11):1270–8. [PubMed: 24061271]
389. Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. *Lancet*. 2011;378(9807):1962–73. [PubMed: 21492929]
390. Feikin DR, Kagucia EW, Loo JD, Link-Gelles R, Puhan MA, Cherian T, et al. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. *PLoS Med*. 2013;10(9):e1001517. [PubMed: 24086113]
391. Jackson LA, Jackson ML, Nelson JC, Neuzil KM, Weiss NS. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. *Int J Epidemiol*. 2006;35(2):337–44. [PubMed: 16368725]
392. Farrington CP. The measurement and interpretation of age-specific vaccine efficacy. *Int J Epidemiol*. 1992;21(5):1014–20. [PubMed: 1468838]
393. Lipsitch M Challenges of vaccine effectiveness and waning studies. *Clin Infect Dis*. 2018 (in press).
394. Crowe E, Pandeya N, Brotherton JM, Dobson AJ, Kisely S, Lambert SB, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-

- control study nested within a population based screening programme in Australia. *BMJ*. 2014;348:g1458. [PubMed: 24594809]
395. Muganga N, Uwimana J, Fidele N, Gahimbare L, Gessner BD, Mueller JE, et al. Haemophilus influenzae type b conjugate vaccine impact against purulent meningitis in Rwanda. *Vaccine*. 2007;25(39–40):7001–5. [PubMed: 17709159]
396. Khagayi S, Tate JE, Onkoba R, Parashar U, Odhiambo F, Burton D, et al. A sham case–control study of effectiveness of DTP-Hib-hepatitis B vaccine against rotavirus acute gastroenteritis in Kenya. *BMC Infect Dis*. 2014;14:77. [PubMed: 24517198]
397. Top FH Jr., Buescher EL, Bancroft WH, Russell PK. Immunization with live types 7 and 4 adenovirus vaccines. II. Antibody response and protective effect against acute respiratory disease due to adenovirus type 7. *J Infect Dis*. 1971;124(2):155–60. [PubMed: 4330998]
398. Edmondson WP, Purcell RH, Gundelfinger BF, Love JW, Ludwig W, Chanock RM. Immunization by selective infection with type 4 adenovirus grown in human diploid tissue culture. II. specific protective effect against epidemic disease. *JAMA*. 1966;195(6):453–9. [PubMed: 4285433]
399. Top FHJ, Dudding BA, Russell PK, Buescher EL. Control of respiratory disease in recruits with types 4 and 7 adenovirus vaccines. *Am J Epidemiol*. 1971;94(2):142–6. [PubMed: 4327997]
400. Centers for Disease Control and Prevention. Measles (Rubeola): Measles cases and outbreaks 2018 [Available from: <https://www.cdc.gov/measles/cases-outbreaks.html>].

**KEY MESSAGES**

- The test-negative design has been increasingly used as an efficient study design to estimate vaccine effectiveness for a range of vaccines and pathogens.
- In our review, we found that clinical case definitions used to enroll patients were similar by pathogens of interest, but the sets of symptoms that defined them varied substantially.
- The test-negative design may be more appropriate for some vaccines and pathogens, but less appropriate in some scenarios for example if vaccination reduces disease severity in breakthrough infections.



**Box 1.****Recommendations on the application of the test-negative design for vaccine effectiveness.**

Recommendations on the application of the test-negative design on non-influenza pathogens


- Select cases and controls that manifest similar degree of severity  
 Patients infected with more severe disease may have higher probability of vaccination and testing compared to those with milder disease. Restricting recruitment criteria to one end of disease spectrum can minimize confounding effect by disease severity. In the case where vaccination affects disease severity, test-negative design may not be appropriate, for example, rotavirus.
- Select controls that are unaffected by vaccination  
 Selecting controls that are positive for infection potentially cross-protected by vaccine of interest, or with increased risk associated with vaccination, is common and may bias results. This is a concern particularly in diseases where one type predominates over another, such as pneumococcal disease. While the depth of knowledge on disease epidemiology increases with research, examining component of vaccine of interest before applying test-negative design may minimize the possibility of selecting inappropriate controls.
- Provide clearly defined case criteria  
 Application of the test-negative design should not rely merely on the availability of laboratory test results. Recruitment of cases and controls based on clearly defined case criteria allows assessment of potential biases, ensures transparency and allows comparison between studies.
- Make appropriate adjustments for confounding and report VE estimates that reflect the causal effect of vaccination in reducing the risk of disease

In a VE test-negative design study, unbiased VE estimates can be obtained under the following assumptions:


1. Vaccination does not affect the probability of becoming a control.
2. Vaccination does not affect the probability of seeking medical care.
3. Absence of misclassification of exposure and outcome status.

In the scenarios where any of these assumptions is not met, appropriate adjustments or analytic strategies might still be able to correct for bias. Unless eligibility criteria for participants are highly restrictive in terms of their demographics and clinical characteristics, measures of association (for example, odds ratios) unadjusted for any potential confounders such as age, comorbidities etc are unlikely to reflect the causal role of vaccination in preventing outcome of


interest, nullifying the objective of estimating the causal effectiveness of vaccination.




**Figure 1.** Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram of the process and results of study screening.



**Figure 2.** Number of included studies by year. Most of the studies identified were of influenza virus. The first eligible study was published in 1980 (16).



**Figure 3.** Study setting by pathogen. Patients could be recruited from outpatient/emergency department, inpatient, or both outpatient and inpatient setting.



**Figure 4.** Choices of clinical case definition by pathogen. Studies that reported recruitment of patients meeting certain clinical case criteria without clarifying specific symptoms were excluded from this figure, including 32 influenza studies (recruited influenza-like illness patients), seven rotavirus studies (recruited gastroenteritis patients), two poliovirus studies (recruited acute flaccid paralysis patients), and one *B. pertussis* study (recruited pertussis-like-illness patients). Human papillomavirus and *N. gonorrhoeae* studies which recruited patients from routine testing were also excluded. Panel A: Other respiratory symptoms include wheezing, whooping cough, apnea, dyspnea, shortness of breath, bronchitis, pharyngitis, pneumonia etc. Other symptoms include complications such as sepsis, stroke, acute exacerbations of chronic respiratory conditions, contact history, etc, or for the case of measles virus, rash, dermal eruption etc. Panel B: Clinical case definition by culture-positive include eight studies which recruited patients with invasive pneumococcal disease and one with acute otitis media. DNA detection may include polymerase chain reaction, or multilocus sequence typing wherever specified. Biochemical tests include bile solubility and optochin susceptibility test. Panel D: Other symptoms include neck stiffness, altered consciousness, other meningeal signs.


Author Manuscript

Author Manuscript


Author Manuscript

Author Manuscript





**Figure 5.** Choices of cases and controls by pathogen. Purple indicates cases and light green indicates controls. If patient samples were tested-positive for pathogen of interest, patient samples may be further tested to identify whether they were infected by vaccine-type or non-vaccine-type. If patients’ samples tested negative for the pathogen of interest, samples may be further tested. Alternative pathogens may be identified or patient samples may be undiagnosed or pan-negative (i.e. negative for all tested pathogen). Studies can be counted more than once when there was more than one choice of cases or controls.



**Figure 6.** Proportion of studies that included age, sex, calendar time, or comorbidities in statistical model to estimate VE.

Table 1.

Definitions of vaccine-type, non-vaccine type, and alternative pathogens according to included studies.

Pathogen of interest	Type of vaccine	Vaccine-type	Non-vaccine type	Alternative pathogens
<b>Influenza virus</b>	Trivalent (TIV), Quadrivalent (QIV) influenza vaccine, Live-attenuated influenza vaccine (LAIV)	Influenza A(H1N1), A(H3N2) and B	Influenza A(H1N1) <sub>seasonal</sub> , A(H3N2) and B	Rhinovirus, respiratory syncytial virus (RSV), human metapneumovirus (hMPV), parainfluenza virus (PIV), bocavirus (BoV), coronavirus (CoV), adenovirus (AdV), enterovirus (EV) and others
<b>Rotavirus</b>	Monovalent influenza vaccine (MIV)	Influenza A(H1N1) <sub>pdm</sub>	G9P, G12P	AdV, norovirus, <i>Campylobacter</i> , <i>Salmonella</i> , <i>Aeromonas</i> , <i>Yersinia enterocolitica</i> and others
	Pentavalent rotavirus vaccine (RV5)	G1P[8], G2P[4], G3P[8], G4P[8], G1P[8]	G2P[4], G3P[8], G4P[8], G1P[8], G9P, G12P	
	Monovalent rotavirus vaccine (RV1)	G1P[8]	Other serotypes than included in the vaccine	Unspecified in included studies
<b>Pneumococcus</b>	7-valent pneumococcal conjugate vaccine (PCV7)	Serotypes 4, 6B, 9V, 14, 18C, 19F, 23F		
	10-valent pneumococcal conjugate vaccine (PCV10)	Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F		
	13-valent pneumococcal conjugate vaccine (PCV13)	Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F		
	14-valent pneumococcal conjugate vaccine (PCV14)	Serotypes 1, 3, 4, 5, 6B, 7F, 9N, 9V, 15B, 14, 18C, 19A, 19F, 22F, 23F, 33F		
	23-valent pneumococcal polysaccharide vaccine (PPV23)	Serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F		
<b>Bordetella pertussis</b>	Whole-cell vaccine and acellular vaccine			
<b>Poliovirus</b>	Monovalent type 1 oral poliovirus vaccine (mOPV1)	Type 1	Type 2 and 3	Parapertussis EV
	Bivalent oral poliovirus vaccine (bOPV)	Type 1 and 3	Type 2	
<b>Vibrio cholerae</b>	Oral cholera vaccine (OCV)	O1, O139		Unspecified in included studies
<b>Measles virus</b>	Measles-containing vaccine (MCV) (e.g. measles, mumps and rubella (MMR))	Genotype A	Genotype B2, B3, C1, C2, D2, D3, D4, D5, D6, D7, D8, D9, D10, D11, G2, G3, H1, H2	Unspecified in included studies
<b>Neisseria meningitidis</b>	Serogroup C contained (e.g. bivalent A, C, tetra(quadri)valent A, C, Y, W-135)	Serogroup C	Serogroup B	<i>Haemophilus influenzae</i> , <i>Streptococcus pneumoniae</i> , etc.
	Serogroup B, C	Serogroup B and C	NA	
<b>Human papillomavirus (HPV)</b>	Bivalent vaccine	Type 16, 18	Other serotypes than included in the vaccine	Unspecified in included studies; test-negative or pan-negative?
	Quadrivalent vaccine	Type 6, 11, 16, 18		
	Nonavalent vaccine	Type 6, 11, 16, 18, 31, 33, 45, 52, 58		

Pathogen of interest	Type of vaccine	Vaccine-type	Non-vaccine type	Alternative pathogens
<i>Neisseria gonorrhoeae</i>	Outer membrane vesicle meningococcal B vaccine (MeNZB)	<i>N. meningococcal</i> serogroup B	<i>N. gonorrhoeae</i>	<i>Chlamydia</i>
<b>Haemophilus influenzae type b (Hib)</b>	Hib conjugated vaccine	Type b	NA	Pneumococcal meningitis
<i>Salmonella</i> Typhi	Typhoid Vi vaccine	<i>S. Typhi</i>	NA	<i>Salmonella</i> Paratyphi

**Table 2.**

Clinical case definitions and clinical samples evaluated for each pathogen.

Pathogen of interest	Clinical case definitions	Number of studies	Clinical samples
<b>Influenza virus</b>	Influenza-like illness (ILI)	143	NP swab, NP aspirate, N swab, T swab, P swab, OP swab
	Acute respiratory illness	47	NP swab, NP aspirate, N swab, T swab, OP swab, N wash, N aspirate
	Severe acute respiratory illness	9	NP swab, NP aspirate, N swab, T swab, N wash, N aspirate, OP swab, P washes
	Pneumonia	4	Sputum, NP swab, OP
	Febrile respiratory illness	4	NP swab, NP aspirate, N swab, N wash, T swab,
	Others*	40	NP swab, NP aspirate, OP swab, N swab, T swab, N aspirate
	Unspecified	6	
<b>Rotavirus</b>	Gastroenteritis	48	Stool, rectal swab
<b>Pneumococcus</b>	Invasive pneumococcal disease (IPD)	19	Normally sterile sites including blood, CSF and pleural fluid
	Pneumonia	4	Blood, urine, sputum, pleural fluid, bronchoalveolar lavage
	Acute otitis	1	Otic fluids
<b>Bordetella pertussis</b>	Pertussis-like-illness	2	NP swab, unspecified
	Unspecified	4	NP swab, unspecified
<b>Poliovirus</b>	Acute flaccid paralysis	4	Stool
<b>Vibrio cholerae</b>	gastroenteritis	4	Stool, rectal swab
<b>Measles virus</b>	Measles-like-illness	2	Blood
<b>Neisseria meningitidis</b>	Meningitis	1	CSF, normally sterile sites
	Unspecified	2	
<b>Human papillomavirus (HPV)</b>	Unspecified	1	Cervical smear
<b>Neisseria gonorrhoeae</b>	Unspecified	1	Unspecified
<b>Haemophilus influenzae type b (Hib)</b>	Meningitis	1	CSF
<b>Salmonella Typhi</b>	Enteric fever	1	Stool

\* Included more than one clinical case definition.

Note: NP: Nasopharyngeal; N: Nasal; T: Throat; P: Pharyngeal; OP: Oropharyngeal; CSF: Cerebrospinal fluid.